[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 2830
1. Levi R, Bar-Sadan M, Albu-Yaron A, Popovitz-Biro R, Houben L, Prior Y, Tenne R: Stability Criteria of Fullerene-like Nanoparticles: Comparing V₂O<sub>5</sub> to Layered Metal Dichalcogenides and Dihalides. Materials (Basel); 2010 Aug 18;3(8):4428-4445

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Stability Criteria of Fullerene-like Nanoparticles: Comparing V₂O<sub>5</sub> to Layered Metal Dichalcogenides and Dihalides.
  • V₂O₅, is a metal oxide compound with a layered structure.
  • The formation mechanism of the NIF-V₂O<sub>5</sub> is discussed in comparison to fullerene-like structures of other layered materials, like IF structures of MoS₂, CdCl₂, and Cs₂O.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Phys Rev Lett. 2000 Jul 3;85(1):146-9 [10991180.001]
  • [Cites] Phys Rev B Condens Matter. 1990 Sep 15;42(8):5289-5293 [9996094.001]
  • [Cites] J Am Chem Soc. 2010 Aug 18;132(32):11214-22 [20698688.001]
  • [Cites] Phys Rev B Condens Matter. 1993 Feb 15;47(8):4215-4220 [10006564.001]
  • [Cites] Angew Chem Int Ed Engl. 2005 Jul 11;44(28):4391-5 [15942965.001]
  • [Cites] Phys Chem Chem Phys. 2009 May 21;11(19):3748-55 [19421487.001]
  • [Cites] Angew Chem Int Ed Engl. 2002 Jul 15;41(14):2446-61 [12203509.001]
  • [Cites] J Am Chem Soc. 2002 Aug 28;124(34):10157-62 [12188680.001]
  • [Cites] J Colloid Interface Sci. 2009 Sep 15;337(2):586-93 [19545878.001]
  • [Cites] Angew Chem Int Ed Engl. 2007;46(4):623-7 [17154434.001]
  • [Cites] Angew Chem Int Ed Engl. 2005 Jul 4;44(27):4169-72 [15937971.001]
  • [Cites] Anal Chem. 2002 Feb 1;74(3):70A-77A [11838700.001]
  • [Cites] Phys Chem Chem Phys. 2007 May 21;9(19):2428-33 [17492107.001]
  • (PMID = 28883335.001).
  • [ISSN] 1996-1944
  • [Journal-full-title] Materials (Basel, Switzerland)
  • [ISO-abbreviation] Materials (Basel)
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Switzerland
  • [Keywords] NOTNLM ; TEM / fullerenes / inorganic / laser ablation / stability / vanadium
  •  go-up   go-down


2. Dai CL, Tai YW, Kao PH: Modeling and Fabrication of Micro FET Pressure Sensor with Circuits. Sensors (Basel); 2007 Nov 19;7(12):3386-3398

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Modeling and Fabrication of Micro FET Pressure Sensor with Circuits.
  • This paper presents the simulation, fabrication and characterization of a microFET (field effect transistor) pressure sensor with readout circuits.
  • Each sensing cell that is circular shape is composed ofan MOS (metal oxide semiconductor) and a suspended membrane, which the suspendedmembrane is the movable gate of the MOS.
  • The CoventorWare is used to simulate thebehaviors of the pressure sensor, and the HSPICE is employed to evaluate the characteristicsof the circuits.
  • The pressure sensor integrated with circuits is manufactured using thecommercial 0.35 μm CMOS (complementary metal oxide semiconductor) process and apost-process.
  • In order to obtain the suspended membranes, the pressure sensor requires apost-CMOS process.
  • The post-process adopts etchants to etch the sacrificial layers in thepressure sensors to release the suspended membranes, and then the etch holes in the pressuresensor are sealed by LPCVD (low pressure chemical vapor deposition) parylene.
  • Thepressure sensor produces a change in current when applying a pressure to the sensing cells.The circuits are utilized to convert the current variation of the pressure sensor into thevoltage output.
  • Experimental results show that the pressure sensor has a sensitivity of 0.032mV/kPa in the pressure range of 0-500 kPa.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28903300.001).
  • [ISSN] 1424-8220
  • [Journal-full-title] Sensors (Basel, Switzerland)
  • [ISO-abbreviation] Sensors (Basel)
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Switzerland
  • [Keywords] NOTNLM ; CMOS-MEMS / micro pressure sensor / readout circuit.
  •  go-up   go-down


3. Jones LC, Tefferi A, Vuong PT, Desmond JC, Hofmann WK, Koeffler HP: Detection of aberrant gene expression in CD34+ hematopoietic stem cells from patients with agnogenic myeloid metaplasia using oligonucleotide microarrays. Stem Cells; 2005 May;23(5):631-7
MedlinePlus Health Information. consumer health - Stem Cells.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Detection of aberrant gene expression in CD34+ hematopoietic stem cells from patients with agnogenic myeloid metaplasia using oligonucleotide microarrays.
  • Agnogenic myeloid metaplasia (AMM) is a clonal stem cell disorder that leads to ineffective hematopoiesis, bone marrow fibrosis, and extramedullary hematopoiesis.
  • Therefore, the aim of this study was to characterize aberrant gene expression in CD34+ hematopoietic stem cells from patients with AMM.
  • We used oligonucleotide microarrays to analyze gene expression profiles in CD34+ hematopoietic stem cells from patients with AMM compared with expression in CD34+ cells from healthy individuals.
  • Using class membership prediction analysis, we identified 75 genes whose expression profiles can accurately differentiate AMM samples from the controls.
  • Using these 75 genes, we were able to discriminate patients with AMM from the controls by hierarchical clustering (Spearman's confidence correlation).
  • The predictive power of these genes was verified by applying the algorithm to an unknown test set containing expression data from eight additional CD34+ samples (four AMM, four control).
  • Our results indicate that a subset of genes may be used to differentiate patients with AMM from healthy individuals.
  • Furthermore, we identify 95 genes whose aberrant expression may be involved in AMM.
  • [MeSH-major] Antigens, CD34. Gene Expression Regulation. Hematopoietic Stem Cells / metabolism. Oligonucleotide Array Sequence Analysis. Primary Myelofibrosis / physiopathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15849170.001).
  • [ISSN] 1066-5099
  • [Journal-full-title] Stem cells (Dayton, Ohio)
  • [ISO-abbreviation] Stem Cells
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / T32 CA-75956
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD34
  •  go-up   go-down


Advertisement
4. Lazarević V, Tiodorović J, Tiodorović-Zivković D, Stanojević M, Popović D, Janković A: Immunophenotyping of amelanotic melanoma. A case report. Acta Dermatovenerol Alp Pannonica Adriat; 2006 Sep;15(3):141-3
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immunophenotyping of amelanotic melanoma. A case report.
  • Amelanotic malignant melanoma (AMM) is a subtype of cutaneous melanoma with little or no pigment upon visual inspection.
  • The lack of pigmentation is the reason for late diagnosis of lesions and a poor prognosis.
  • We report a case of a 55-year-old female with an AMM diagnosed by immunophenotyping.
  • So far there are no signs of a recurrence.
  • In doubtful cases, immunophenotyping with monoclonal antibodies HMB-45 and S-100 is important for confirming the correct diagnosis of AMM.
  • [MeSH-major] Melanoma, Amelanotic / diagnosis. Skin Neoplasms / diagnosis
  • [MeSH-minor] Antibodies / therapeutic use. Antibodies, Monoclonal / therapeutic use. Combined Modality Therapy. Diagnosis, Differential. Female. Humans. Immunophenotyping. Keratins / immunology. Middle Aged. S100 Proteins / immunology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17053850.001).
  • [ISSN] 1318-4458
  • [Journal-full-title] Acta dermatovenerologica Alpina, Pannonica, et Adriatica
  • [ISO-abbreviation] Acta Dermatovenerol Alp Pannonica Adriat
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Slovenia
  • [Chemical-registry-number] 0 / Antibodies; 0 / Antibodies, Monoclonal; 0 / S100 Proteins; 68238-35-7 / Keratins
  •  go-up   go-down


5. Frank P, Benfatto M, Hedman B, Hodgson KO: Solution [Cu(amm)]2+ is a strongly solvated square pyramid: a full account of the copper K-edge XAS spectrum within single-electron theory. Inorg Chem; 2008 May 19;47(10):4126-39
Hazardous Substances Data Bank. Ammonia .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Solution [Cu(amm)]2+ is a strongly solvated square pyramid: a full account of the copper K-edge XAS spectrum within single-electron theory.
  • The solution structure of Cu(II) in 4 M aqueous ammonia, [Cu(amm)](2+), was assessed using copper K-edge extended X-ray absorption fine structure (EXAFS) and Minuit XANes (MXAN) analyses.
  • Each approach converged to the same axially elongated square pyramid, 4 x Cu-Neq=2.00+/-0.02 A and 1 x Cu-Nax=2.16+/-0.02 A (EXAFS) or 2.20+/-0.07 A (MXAN), with strongly localized solvation shells.
  • The prominent shoulder and duplexed maximum of the rising K-edge XAS of [Cu(amm)](2+) primarily reflect the durable and well-organized solvation shells, not found around [Cu(H2O)5](2+), rather than two-electron shakedown transitions.
  • Not accounting for solvent scattering thus may confound XAS-based estimates of metal-ligand covalency.
  • [Cu(amm)](2+) continues the dissymmetry previously found for the solution structure of [Cu(H2O)5](2+), again contradicting the rack-bonding theory of blue copper proteins.

  • Hazardous Substances Data Bank. COPPER, ELEMENTAL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18426203.001).
  • [ISSN] 0020-1669
  • [Journal-full-title] Inorganic chemistry
  • [ISO-abbreviation] Inorg Chem
  • [Language] ENG
  • [Grant] United States / NCRR NIH HHS / RR / P41 RR001209; United States / NCRR NIH HHS / RR / RR-01209; United States / NCRR NIH HHS / RR / RR001209
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cations, Divalent; 0 / Solutions; 7664-41-7 / Ammonia; 789U1901C5 / Copper
  •  go-up   go-down


6. Hillengass J, Zechmann C, Bäuerle T, Wagner-Gund B, Heiss C, Benner A, Ho A, Neben K, Hose D, Kauczor HU, Goldschmidt H, Delorme S, Moehler T: Dynamic contrast-enhanced magnetic resonance imaging identifies a subgroup of patients with asymptomatic monoclonal plasma cell disease and pathologic microcirculation. Clin Cancer Res; 2009 May 1;15(9):3118-25
MedlinePlus Health Information. consumer health - Multiple Myeloma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Dynamic contrast-enhanced magnetic resonance imaging identifies a subgroup of patients with asymptomatic monoclonal plasma cell disease and pathologic microcirculation.
  • PURPOSE: The aim of our study was to investigate whether dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) allows visualization of changes in microcirculation between healthy controls on the one side and early/advanced stages of plasma cell disease on the other.
  • EXPERIMENTAL DESIGN: We examined a group of 222 individuals consisting of 60 patients with monoclonal gammopathy of undetermined significance (MGUS), 65 patients with asymptomatic multiple myeloma (aMM), 75 patients with newly diagnosed symptomatic MM (sMM), and 22 healthy controls with DCE-MRI of the lumbar spine.
  • RESULTS: A continuous increase in microcirculation parameters amplitude A and exchange rate constant kep reflecting vascular volume and permeability, respectively, was detected from normal controls over MGUS and aMM to sMM.
  • For A and kep, significant differences were found between controls and aMM (P = 0.03 and P = 0.004, respectively) as well as controls and sMM (P = 0.001 and P < 0.001, respectively).
  • Although diffuse microcirculation patterns were found in healthy controls as well as MGUS and MM, a pattern with focal hotspots was exclusively detected in 42.6% of sMM and in 3 MGUS and 3 aMM patients.
  • MGUS and aMM patients with increased microcirculation patterns showed significantly higher bone marrow plasmocytosis compared with patients with a low microcirculation pattern.
  • Pathologic DCE-MRI findings correlate with adverse prognostic factors and DCE-MRI identifies a distinct group of patients with increased microcirculation parameters in aMM and MGUS patients.
  • [MeSH-major] Bone Marrow / blood supply. Contrast Media. Magnetic Resonance Imaging. Multiple Myeloma / diagnosis. Paraproteinemias / diagnosis. Plasma Cells / pathology

  • MedlinePlus Health Information. consumer health - MRI Scans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19366830.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Contrast Media
  •  go-up   go-down


7. Stanko JP, Enoch RR, Rayner JL, Davis CC, Wolf DC, Malarkey DE, Fenton SE: Effects of prenatal exposure to a low dose atrazine metabolite mixture on pubertal timing and prostate development of male Long-Evans rats. Reprod Toxicol; 2010 Dec;30(4):540-9
Hazardous Substances Data Bank. ATRAZINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The present study examines the postnatal reproductive development of male rats following prenatal exposure to an atrazine metabolite mixture (AMM) consisting of the herbicide atrazine and its environmental metabolites diaminochlorotriazine, hydroxyatrazine, deethylatrazine, and deisopropylatrazine.
  • Pregnant Long-Evans rats were treated by gavage with 0.09, 0.87, or 8.73mg AMM/kg body weight (BW), vehicle, or 100mg ATR/kg BW positive control, on gestation days 15-19.
  • Preputial separation was significantly delayed in 0.87 mg and 8.73mg AMM-exposed males.
  • AMM-exposed males demonstrated a significant treatment-related increase in incidence and severity of inflammation in the prostate on postnatal day (PND) 120.
  • A dose-dependent increase in epididymal fat masses and prostate foci were grossly visible in AMM-exposed offspring.
  • These results indicate that a short, late prenatal exposure to mixture of chlorotriazine metabolites can cause chronic prostatitis in male LE rats.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Published by Elsevier Inc.
  • [Cites] Toxicol Sci. 1999 Nov;52(1):68-79 [10568700.001]
  • [Cites] Environ Monit Assess. 2009 Aug;155(1-4):281-307 [18677547.001]
  • [Cites] Toxicol Sci. 2000 Feb;53(2):297-307 [10696778.001]
  • [Cites] Toxicol Sci. 2000 May;55(1):152-61 [10788570.001]
  • [Cites] Toxicol Sci. 2000 Nov;58(1):50-9 [11053540.001]
  • [Cites] Toxicol Sci. 2000 Dec;58(2):366-76 [11099648.001]
  • [Cites] J Androl. 2001 Jan-Feb;22(1):142-8 [11191080.001]
  • [Cites] Toxicol Sci. 2002 Jun;67(2):198-206 [12011479.001]
  • [Cites] J Reprod Immunol. 2003 Feb;58(1):1-26 [12609522.001]
  • [Cites] Environ Sci Technol. 2003 Mar 1;37(5):944-50 [12666925.001]
  • [Cites] Toxicol Sci. 2003 Nov;76(1):190-200 [12970575.001]
  • [Cites] Toxicol Pathol. 2004 Jan-Feb;32(1):79-90 [14713552.001]
  • [Cites] Toxicol Appl Pharmacol. 2004 Feb 15;195(1):23-34 [14962502.001]
  • [Cites] Invest Urol. 1976 Jul;14(1):20-2 [955845.001]
  • [Cites] Biol Reprod. 1977 Sep;17(2):298-303 [889997.001]
  • [Cites] J Steroid Biochem. 1979 Jul;11(1C):833-8 [491646.001]
  • [Cites] Prog Clin Biol Res. 1981;75B:9-18 [6275416.001]
  • [Cites] J Steroid Biochem. 1987;27(4-6):1095-100 [3695505.001]
  • [Cites] J Steroid Biochem. 1989 Jul;33(1):141-6 [2761262.001]
  • [Cites] Endocrinology. 1977 Mar;100(3):729-37 [401024.001]
  • [Cites] J Toxicol Environ Health. 1994 Oct;43(2):169-82 [7932847.001]
  • [Cites] Reprod Toxicol. 1996 Jul-Aug;10(4):257-64 [8829248.001]
  • [Cites] Steroids. 1999 Sep;64(9):672-8 [10503727.001]
  • [Cites] Birth Defects Res B Dev Reprod Toxicol. 2005 Jun;74(3):277-85 [15954088.001]
  • [Cites] Chem Res Toxicol. 2006 May;19(5):692-700 [16696572.001]
  • [Cites] Endocrinology. 2006 Jun;147(6 Suppl):S18-24 [16690811.001]
  • [Cites] Int J Occup Environ Health. 2006 Jul-Sep;12(3):260-7 [16967834.001]
  • [Cites] Toxicol Appl Pharmacol. 2007 Feb 1;218(3):238-48 [17204298.001]
  • [Cites] Environ Health Perspect. 2007 Apr;115(4):541-7 [17450222.001]
  • [Cites] Birth Defects Res B Dev Reprod Toxicol. 2007 Apr;80(2):98-112 [17443714.001]
  • [Cites] Endocrinology. 2007 Jul;148(7):3185-95 [17431008.001]
  • [Cites] J Androl. 2008 May-Jun;29(3):304-11 [17978342.001]
  • [Cites] Environ Health Perspect. 2008 Jul;116(7):923-9 [18629315.001]
  • [ErratumIn] Reprod Toxicol. 2011 Jul;32(1):146-7
  • (PMID = 20727709.001).
  • [ISSN] 1873-1708
  • [Journal-full-title] Reproductive toxicology (Elmsford, N.Y.)
  • [ISO-abbreviation] Reprod. Toxicol.
  • [Language] eng
  • [Grant] United States / Intramural NIH HHS / / Z99 ES999999
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Herbicides; 0 / Pesticide Residues; QJA9M5H4IM / Atrazine
  • [Other-IDs] NLM/ NIHMS230835; NLM/ PMC2993819
  •  go-up   go-down


8. Qie YQ, Wang JL, Liu W, Shen H, Chen JZ, Zhu BD, Xu Y, Zhang XL, Wang HH: More vaccine efficacy studies on the recombinant Bacille Calmette-Guerin co-expressing Ag85B, Mpt64 and Mtb8.4. Scand J Immunol; 2009 Apr;69(4):342-50
MedlinePlus Health Information. consumer health - Tuberculosis.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The immunogenicity of the recombinant Bacille Calmette-Guerin: rBCG-Ag85B-Mpt64(190-198)-Mtb8.4 (rBCG-AMM) was evaluated in our previous study.
  • This paper compares the protective efficacy of rBCG-AMM, rBCG-A which overexpresses Ag85B and BCG in C57BL/6 mice.
  • There was no significant difference in proliferation characteristics among rBCG-AMM, rBCG-A and BCG.
  • The growth characteristics of rBCG-AMM in host tissue were identical to control BCG, suggesting the improved protective efficacy was directly related to the expression of the Ag85B-Mpt64(190-198)-Mtb8.4 fusion protein.
  • The protective experiment demonstrated that rBCG-AMM could confer similar or even better protective efficacy against Mycobacterium tuberculosis infection compared with BCG or rBCG-A as evaluated by bacterial organ loads, lung histopathology and net weight gain or loss.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19284499.001).
  • [ISSN] 1365-3083
  • [Journal-full-title] Scandinavian journal of immunology
  • [ISO-abbreviation] Scand. J. Immunol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, Bacterial; 0 / BCG Vaccine; 0 / Recombinant Fusion Proteins; 0 / Vaccines, Synthetic
  •  go-up   go-down


9. Guliants VV, Bhandari R, Hughett AR, Bhatt S, Schuler BD, Brongersma HH, Knoester A, Gaffney AM, Han S: Probe molecule chemisorption-low energy ion scattering study of surface active sites present in the orthorhombic Mo-V-(Te-Nb)-O catalysts for propane (amm)oxidation. J Phys Chem B; 2006 Mar 30;110(12):6129-40
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Probe molecule chemisorption-low energy ion scattering study of surface active sites present in the orthorhombic Mo-V-(Te-Nb)-O catalysts for propane (amm)oxidation.
  • These orthorhombic phases exhibited vastly different behavior in propane (amm)oxidation reactions and, therefore, represented highly promising model systems for the study of the surface active sites.
  • These findings strongly suggested that the bulk orthorhombic Mo-V-Te-Nb-O structure may function as a support for the unique active and selective surface monolayer in propane (amm)oxidation.
  • Finally, the present study strongly indicated that chemical probe chemisorption combined with low energy ion scattering (LEIS) is a novel and highly promising surface characterization technique for the investigation of the active surface sites present in the bulk mixed metal oxides.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16553426.001).
  • [ISSN] 1520-6106
  • [Journal-full-title] The journal of physical chemistry. B
  • [ISO-abbreviation] J Phys Chem B
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


10. Scolozzi P, Herzog G, Jaques B: Re: Shehata EAA, Medra AMM. Modified bimaxillary distraction osteogenesis: A technique to correct facial asymmetry. Br J Oral Maxillofac Surg 2006;45:471-7. Br J Oral Maxillofac Surg; 2008 Mar;46(2):170-1

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Re: Shehata EAA, Medra AMM. Modified bimaxillary distraction osteogenesis: A technique to correct facial asymmetry. Br J Oral Maxillofac Surg 2006;45:471-7.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentOn] Br J Oral Maxillofac Surg. 2007 Sep;45(6):471-7 [17161890.001]
  • (PMID = 17618714.001).
  • [ISSN] 1532-1940
  • [Journal-full-title] The British journal of oral & maxillofacial surgery
  • [ISO-abbreviation] Br J Oral Maxillofac Surg
  • [Language] eng
  • [Publication-type] Comment; Letter
  • [Publication-country] Scotland
  •  go-up   go-down


11. Martin-Eauclaire MF, Alami M, Giamarchi A, Missimilli V, Rosso JP, Bougis PE: A natural anatoxin, Amm VIII, induces neutralizing antibodies against the potent scorpion alpha-toxins. Vaccine; 2006 Mar 15;24(12):1990-6

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A natural anatoxin, Amm VIII, induces neutralizing antibodies against the potent scorpion alpha-toxins.
  • In this study, we have used Amm VIII, a natural anatoxin from the scorpion Androctonus mauretanicus mauretanicus, to elicit specific polyclonal antibodies in rabbit.
  • We have shown that the anti-Amm VIII serum prevents the association of 125I-AaH II with its receptor and is able to remove 125I-AaH II already bound to its site (the half-life of the complex 125I-AaH II-receptor site was 12 min in the absence of anti-Amm VIII serum but decreased to only 2 min in the presence of anti-Amm VIII serum).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16325311.001).
  • [ISSN] 0264-410X
  • [Journal-full-title] Vaccine
  • [ISO-abbreviation] Vaccine
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Amm VIII toxin, Androctonus mauretanicus mauretanicus; 0 / Antibodies; 0 / Scorpion Venoms; 0 / Toxoids; 0 / Vaccines, Synthetic
  •  go-up   go-down


12. Alami M, Céard B, Legros C, Bougis PE, Martin-Eauclaire MF: Genomic characterisation of the toxin Amm VIII from the scorpion Androctonus mauretanicus mauretanicus. Toxicon; 2006 Apr;47(5):531-6
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Genomic characterisation of the toxin Amm VIII from the scorpion Androctonus mauretanicus mauretanicus.
  • The genomic DNA sequence encoding the scorpion toxin Amm VIII was amplified from genomic DNA of the scorpion Androctonus mauretanicus mauretanicus from Morocco, subcloned and sequenced.
  • An intron, with a high A+T content (73.5%), split a Gly codon at the end of the precursor signal peptide and the consensus GT/AG splice junction was identified in the Amm VIII gene.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16533515.001).
  • [ISSN] 0041-0101
  • [Journal-full-title] Toxicon : official journal of the International Society on Toxinology
  • [ISO-abbreviation] Toxicon
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Amm VIII toxin, Androctonus mauretanicus mauretanicus; 0 / Scorpion Venoms
  •  go-up   go-down


13. Oyama MA, Sisson DD: Assessment of cardiac chamber size using anatomic M-mode. Vet Radiol Ultrasound; 2005 Jul-Aug;46(4):331-6

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Anatomic M-mode (AMM) is an echocardiographic technique that is capable of generating M-mode studies from two-dimensional (2D) cine loops.
  • Unlike conventional M-mode (CMM) whose scan line must lie along the axis of the ultrasound signal, AMM produces M-mode studies independent of the orientation of the ultrasound beam.
  • We sought to determine the ability of AMM to measure cardiac dimensions in normal dogs and to assess the accuracy and variability of AMM and CMM vs. 2D measurements.
  • Thirty-eight healthy dogs underwent physical exam and 2D, CMM, and AMM echocardiographic studies.
  • Results of the AMM and CMM study were compared with the 2D study via linear regression and calculation of a coefficient of correlation.
  • AMM increased the level of correlation with both the left ventricular dimensions and LAD.
  • Bland-Altman analysis revealed that AMM increased the level of agreement with 2D measurements and CMM greatly underestimated LAD vs. AMM.
  • In healthy dogs, cardiac AMM measurements are associated with greater accuracy and less variability than CMM.
  • AMM has the potential to improve quantification of cardiac dimensions.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16229436.001).
  • [ISSN] 1058-8183
  • [Journal-full-title] Veterinary radiology & ultrasound : the official journal of the American College of Veterinary Radiology and the International Veterinary Radiology Association
  • [ISO-abbreviation] Vet Radiol Ultrasound
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


14. Alvarenga L, Moreau V, Felicori L, Nguyen C, Duarte C, Chavez-Olortegui C, Molina F, Martin-Eauclaire MF, Granier C: Design of antibody-reactive peptides from discontinuous parts of scorpion toxins. Vaccine; 2010 Jan 22;28(4):970-80
Immune Epitope Database and Analysis Resource. gene/protein/disease-specific - Related Immune Epitope Information .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The Amm VIII protein was previously isolated from the venom of the scorpion Androctonus mauretanicus mauretanicus.
  • Despite 87% identity with AaH II, the most toxic alpha-type scorpion toxin, Amm VIII is not toxic to mice.
  • However, antisera against Amm VIII protect mice from AaH II lethal action.
  • Here, we report that the Amm VIII protein elicits antibodies that only recognize discontinuous-type epitopes since we could not observe any antibody binding to overlapping 12-mer peptides covering the whole Amm VIII sequence.
  • By using a new bioinformatic tool, 24 peptides mimicking discontinuous regions of Amm VIII were designed in silico, then prepared by Spot synthesis.
  • Seven of these discontinuous-continuous peptides were recognized by anti-Amm VIII antibodies.
  • Analysis of the 3D location of the segments that compose the antigenically reactive discontinuous-continuous peptides, allowed us to group those antigenic segments into three regions of Amm VIII, putatively corresponding to discontinuous antigenic regions of alpha-type scorpion toxins.
  • Anti-Amm VIII antibodies were also found to cross-react towards several of the discontinuous-continuous peptides designed from the AaH II structure, pointing to a possible involvement of the corresponding discontinuous epitopes in the capacity displayed by anti-Amm VIII antibodies to neutralize AaH II.
  • The position of the reactive segments in the structural context of scorpion toxins highlights the antigenic properties of the Amm VIII anatoxin and concurs to explain the capacity of anti-Amm VIII antibodies to neutralize the potent AaH II toxin.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19962461.001).
  • [ISSN] 1873-2518
  • [Journal-full-title] Vaccine
  • [ISO-abbreviation] Vaccine
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Amm VIII toxin, Androctonus mauretanicus mauretanicus; 0 / Antibodies, Neutralizing; 0 / Antitoxins; 0 / Epitopes; 0 / Scorpion Venoms
  •  go-up   go-down


15. Mesa RA, Kantarjian H, Tefferi A, Cheville A, Pardanani A, Levy R, Erickson-Viitanen S, Thomas D, Cortes J, Borthakur G, Verstovsek S: Functional assessment of performance status in patients with myelofibrosis (MF): Utility and feasibility of the 6-minute walk test (6MWT). J Clin Oncol; 2009 May 20;27(15_suppl):7083

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Functional assessment of performance status in patients with myelofibrosis (MF): Utility and feasibility of the 6-minute walk test (6MWT).
  • : 7083 Background: Patients with Myelofibrosis (MF) suffer from significant fatigue, constitutional symptoms and splenomegaly (Mesa et. al.
  • The 6MWT was administered in standardized fashion (American Thoracic Society: observed laps of a 30 - 35 meter long course, indoors, level, without encouragement), and then repeated for further validation.
  • Cancer 1999) embedded in the MFSAF) showed patients with a higher BFI (i.e., more fatigued) had more impairment in the 6MWT than those with low BFI scores.
  • Validation of the ability of the 6MWT to measure functional improvements in MF patients as a response to novel therapy trials is planned.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961476.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


16. Oettle H, Hilbig A, Seufferlein T, Schmid RM, Luger T, von Wichert G, Schmaus S, Heinrichs H, Schlingensiepen K: Interim results of the phase I/II study of trabedersen (AP 12009) in patients with pancreatic carcinoma, malignant melanoma, or colorectal carcinoma. J Clin Oncol; 2009 May 20;27(15_suppl):4619

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Interim results of the phase I/II study of trabedersen (AP 12009) in patients with pancreatic carcinoma, malignant melanoma, or colorectal carcinoma.
  • METHODS: 33 patients with advanced pancreatic carcinoma (stage IVA/IVB) (N=23), malignant melanoma (stage III/IV) (N=5) or colorectal carcinoma (stage III/IV) (N=5) were treated with trabedersen as 2nd-4th-line treatment.
  • PRIMARY STUDY OBJECTIVE: maximum tolerated dose (MTD); secondary objectives: safety and tolerability, pharmacokinetics and antitumor activity.
  • Of the 5 melanoma patients one from the 1st schedule showed stable disease and lived for 13.8 months; 3 patients from the 2nd schedule are still alive.
  • Median overall survival (mOS) for pancreatic carcinoma patients in the 1st schedule was 6.8 months.
  • Current mOS for pancreatic carcinoma patients in cohort 1 (N=5) of the 2nd schedule is 13.2 months; 2 of these patients are alive, one with stable disease 14.8 months after begin of trabedersen treatment.
  • A randomized, active-controlled phase II study compared to standard therapy in patients with pancreatic carcinoma is in preparation; another one in malignant melanoma is being planned.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964197.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


17. Jackman DM, Cioffredi L, Lindeman NI, Morse LK, Lucca J, Weckstein D, Huberman MS, Lynch TJ, Johnson BE, Janne PA: Phase II trial of erlotinib in chemotherapy-naive women with advanced pulmonary adenocarcinoma. J Clin Oncol; 2009 May 20;27(15_suppl):8065

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: Eligible pts were chemotherapy-naïve women, stage IIIB/ IV, PS 0-2, adenocarcinoma, and w/ available tissue for analysis of EGFR mutation status.
  • Pts received erlotinib 150 mg PO daily until disease progression or unacceptable toxicity.
  • Primary endpoint was response rate (RR).
  • EFFICACY: Response (n=84): 0 CR, 27 PR (RR 32%), 27 SD, 23 PD.
  • 7 pts not evaluable (5 tox, 1 non-progression death, 1 withdrawn consent).
  • Median TTP was 5.6 months (95% CI 4.1-7.4 mos), and median OS was 22.7 months (95% CI 15.8 - 26.0 mos).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962638.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


18. Diaz Romero C, Olvera N, Martínez H, Mtz Cedillo J, Cuellar M, Morales R, Álvarez M, Segura B, De la Garza J, Aguilar P: Paclitaxel plus carboplatin (PC) in patients with metastatic melanoma (MM): Experience in a single institution. J Clin Oncol; 2009 May 20;27(15_suppl):e20019

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Paclitaxel plus carboplatin (PC) in patients with metastatic melanoma (MM): Experience in a single institution.
  • : e20019 Background: The number of agents active in patients with metastatic melanoma is limited and cure is not an objective for treatment at this stage, so that clinical benefit in these patients is the most important.
  • The regimen was weekly paclitaxel (at a dose of 80 mg/m2) received on days 1, 8, and 15 of a 21-day cycle and carboplatin (AUC 5) on day 1.
  • Objective partial response were obtained in 4 patients (25%); 8 stable disease (50%) at least four months.
  • Progression disease was in 4 patients (25%).
  • The median time to disease progression for the entire group was 4.2 months (range, 1-11 mos), with a median overall survival of 8.1 months (range, 5.6-10.5 mos).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962551.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


19. Campos LT, Nemunaitis J, Stephenson J, Richards D, Barve M, Gardner L, Niecestro R, Sportelli P: Phase II study of single agent perifosine in patients with hepatocellular carcinoma (HCC). J Clin Oncol; 2009 May 20;27(15_suppl):e15505

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In a phase III randomized study, sorafenib demonstrated a 2% partial response (PR) rate with a median time to symptomatic progression of 4.1 months (mos) and radiologic progression of 5.5 mos, however patients (pts) had not received prior systemic treatment.
  • Peri was evaluated in a phase II multi-disease trial where 558 pts were randomized to daily vs. weekly schedules of Peri (50/100 mg daily or 900/1,200 mg weekly) with 42 of the pts having HCC.
  • Normal organ / marrow function required.
  • Primary outcome analyses included median time to progression (TTP) and disease control rate (DCR; CR+PR+SD > 12 weeks).
  • One patient achieved a PR (3%) and 15 (47%) had stable disease > 12 weeks; overall DCR of 50%.
  • As of 12/08, one patient remains active at 12 mos.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962225.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


20. Vidaurre T, Wilkerson J, Bates SE, Simon R, Fojo AT: Value of stable disease (SD) in drug development of targeted therapies (TGT). J Clin Oncol; 2009 May 20;27(15_suppl):2509

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Value of stable disease (SD) in drug development of targeted therapies (TGT).
  • Aware the acceptance of SD as a measure of activity led to its being increasingly reported with traditional cytotoxic agents (CTX), we set about to methodically compare the occurrence of SD in phase II trials of TGT and CTX.
  • Thirty-eight properties including CR, PR, SD, PFS, and OS were recorded for each study.
  • For CTX vs. TGT, the median numbers of pts/study was 47.1 vs. 51.9; median PFS, 5.55 vs. 4.54 mos; and median OS, 12.55 vs. 12.88 mos.
  • The overall response rate (CR + PR) was higher with CTX than with TGT (29.4% vs. 13.3%) and demonstrated a strong correlation (p<0.0001) of uncertain importance with PFS and OS for all therapies.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961963.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


21. Faderl S, Thomas DA, Gandhi V, Huang X, Borthakur G, O'Brien S, Ravandi F, Plunkett W, Bretz JL, Kantarjian HM: Results of a phase I study of clofarabine (CLO) plus cyclophosphamide (CY) in adult patients (pts) with relapsed and/or refractory acute lymphoblastic leukemia (ALL). J Clin Oncol; 2009 May 20;27(15_suppl):7020

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Results of a phase I study of clofarabine (CLO) plus cyclophosphamide (CY) in adult patients (pts) with relapsed and/or refractory acute lymphoblastic leukemia (ALL).
  • METHODS: Pts ≥ 21 years (yrs) with primary refractory or relapsed ALL, NYHA class < 3, and a cardiac ejection fraction ≥ 45% were eligible.
  • Seven (23%) pts were primary refractory.
  • Among the remainder, preceding median remission duration was 8.6 mos (1-39 mos).
  • Evaluable for response were 28 pts: 3 CR (one pt in cohort 1) and 1 marrow CR (OR 14%).
  • One pt had Ph+ ALL, and one was primary refractory to HCVAD.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961382.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


22. Ardalan B, Feagans M, Mezentsev D, Jones C, Subbarayan PR, Walker G, Sapp M, Stephenson K, Ness J, Franceschi D, Livingstone A: Phase II study of bevacizumab (B), camptosar (I), high-dose 24-hour continuous intravenous infusion of floxuridine (F) and leucovorin (L) in patients with previously untreated metastatic colon cancer. (B-IFL). J Clin Oncol; 2009 May 20;27(15_suppl):e15114

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • : e15114 Background: In a previous study, IFL was used in patients (pt) with untreated metastatic colon cancer and a median overall survival (MOS) of 31 months (m).
  • The primary end-point is MOS Methods: Each cycle involved 6 weeks (wks) of treatment.
  • The treatment cycle consisted of a 90 minute infusion of I (110 mg/m<sup>2</sup>), followed by a 24 hour infusion of F (120mg/kg) and L (500 mg/m<sup>2</sup>) on wks 1, 2, 4, 5.
  • Quality of life data and thymidylate synthase expression in peripheral blood mononuclear cells was monitored Results: 22 pt with a median age of 57 (38-82), 11 males and 11 females were enrolled.
  • 8 pt (36%) had bilobar liver disease and involvement of 1 other organ, 6 pt (27%) had bilobar liver disease with involvement of ≥ 2 other organs; 5 pt (23.5%) had bilobar liver disease; 2 pt (9%) had abdominal carcinomatosis; 1 pt (4.5 %) had involvement in one liver lobe.
  • Grade (Gr) 4 toxicity: pulmonary embolus 1 pt (5%) incidental CT finding.
  • 5 pt have died due to progression of disease.
  • The estimated median time to progression was 13 m with corresponding lower 95% confidence bound of 8.4 m.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27960848.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


23. Vickers MM, Choueiri TK, Zama I, Cheng T, North S, Knox JJ, Kollmannsberger C, McDermott DF, Rini BI, Heng DY: Failure of initial VEGF-targeted therapy in metastatic renal cell carcinoma (mRCC): What next? J Clin Oncol; 2009 May 20;27(15_suppl):5098

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RESULTS: 645 patients with mRCC who received initial VEGF-targeted therapy were identified (sunitinib, sorafenib or bevacizumab) and had a median follow-up of 25 mos.
  • Of these, 218 patients (34%) received second-line targeted therapy: the median age was 62 yrs (range, 41-87), median KPS was 90%, 90% had prior nephrectomy, 3.8% had non-clear cell histology, 5.8% had brain metastases and 79% had > 1 metastatic site.
  • Patient characteristics were similar aside from more non-clear cell histology in patients receiving second-line mTOR-inhibiting agents (14% vs 3% p = 0.045).
  • The median time to treatment failure (TTF) of second-line therapy was 4.9 mos for anti-VEGF therapy and 2.5 mos for mTOR inhibitors (p = 0.014).
  • However, patient selection may account for this finding and overall survival was not significantly different.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964309.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


24. Van Schil PE, Baas P, Gaafar R, Maat AP, van de Pol M, Hasan B, Klomp HM, Abdelrahman AM, Welch J, Van Meerbeeck J, EORTC Lung Cancer Group: Phase II feasibility trial of induction chemotherapy (ICT) followed by extrapleural pneumonectomy (EPP) and postoperative radiotherapy (PORT) for cT3N1M0 or less malignant pleural mesothelioma (MPM) (EORTC 08031). J Clin Oncol; 2009 May 20;27(15_suppl):7509

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II feasibility trial of induction chemotherapy (ICT) followed by extrapleural pneumonectomy (EPP) and postoperative radiotherapy (PORT) for cT3N1M0 or less malignant pleural mesothelioma (MPM) (EORTC 08031).
  • : 7509 Background: MPM is a highly lethal disease and the role of EPP in the treatment of early stage, potentially resectable MPM remains controversial.
  • Non-progressing patients (pts) underwent EPP followed by PORT (54Gy, 30 fractions).
  • Primary endpoint was "success of treatment" defined as a patient receiving the full protocol treatment, still alive 90 days after end of treatment without progression and without grade (G) 3-4 toxicity.
  • R0/1/2: 30/10/3, 6 were re-operated, pT0/1/2/3/4: 2/5/19/15/4, pN0/1/2/3: 34/2/6/2, 90-day mortality: 3 pts (6.5%); in 38 pts (83%) postoperative complications occurred.
  • After median follow- up of 19.3 months (mos) median overall survival time was 18.4 mos (95% CI 14.8-NR) and median progression-free survival was 13.9 mos (95% CI 10.9-17.1).
  • Only 24 pts (42%) met the definition of success (one-sided 90% CI 0.36-1.00).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963479.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


25. Schwartz GK, Robertson S, Shen A, Wang E, Pace L, Dials H, Mendelson D, Shannon P, Gordon M: A phase I study of XL281, a selective oral RAF kinase inhibitor, in patients (Pts) with advanced solid tumors. J Clin Oncol; 2009 May 20;27(15_suppl):3513

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The maximum tolerated dose (MTD) was expanded to 10 pts each with colorectal (CRC), melanoma, papillary thyroid (PTC) and NSCLC.
  • One pt with an ocular melanoma demonstrated a cPR of 4 mos duration.
  • Twelve pts had SD (3 -17+ mos), including 2 with I<sup>131</sup>-refractory PTC harboring BRAF V600E mutations (15+ and 17+ mos).
  • At the MTD, paired biopsies from 4 pts (3 melanoma, 1 NSCLC) show an average 72 % decrease in pMEK, 68 % decrease in pERK, 24 % decrease in Ki67 (proliferation) and 64 % increase in TUNEL (apoptosis).
  • Three of 6 evaluable pts in the MTD cohort show SD at first assessment, including 1 melanoma pt with a NRAS Q61R mutation who showed a 20% decrease in target lesions.
  • One cPR occurred in an ocular melanoma subject, and clinical benefit (PR or SD) occurred in 43% (13/30) of pts in the dose-escalation phase.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961303.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


26. Frankenthaler A, Lee M, Seery V, Renzi S, Kinnaman M, Liu V, Friedman E, Atkins MB, Cutaneous Oncology Program: Impact of concomitant immunosuppression on the presentation and prognosis of patients with melanoma. J Clin Oncol; 2009 May 20;27(15_suppl):9070

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Impact of concomitant immunosuppression on the presentation and prognosis of patients with melanoma.
  • : 9070 Background: Melanoma has been reported to be susceptible to immune control.
  • Therefore, we hypothesized that concomitant immune suppression might impact the course of the disease.
  • METHODS: We examined the Beth Israel Deaconess Medical Center Cutaneous Oncology Program database for pts with immune suppression at the time of melanoma diagnosis.
  • The demographics and stage of these pts were compared to those in the database as a whole.
  • In addition, 3 controls matched for age, gender, stage and tumor location were identified for each case and disease outcome was compared between cases and controls.
  • RESULTS: 19 pts were identified with melanoma and concomitant immune suppression in a database of 1820 melanoma pts.
  • Melanoma stages at diagnosis were in situ 1, IB 7, IIA 1, IIB 1, IIIB 3, IIIC 5, and IV 1.
  • Compared to the database as a whole, cases were more likely to be female (84% vs 45%) and have a higher disease stage (42% stage IIIB/C vs 26%).
  • In addition, more cases appeared to have an amelanotic primary (21% vs. 5.4%) or an atypical mole syndrome (21% vs 10.2%).
  • For pts who relapsed, the cases had a shorter disease free interval (DFI) (2.1 vs 9.7 yrs) than the controls.
  • At a median f/up of 52 mos, 37% of the cases had relapsed and all of these pts had died.
  • At a median f/up of 76 mos, 30% of the controls had relapsed yet only 47% of these pts had died.
  • As a consequence, cases appeared more likely to have died of their disease than controls (42% vs 23%) (p=0.10).
  • CONCLUSIONS: Compared to the general melanoma population, pts with concomitant immune suppression appear more likely to be female, have an amelanotic primary or atypical mole syndrome and more advanced disease at presentation.
  • Thus, diagnosis and treatment of a primary melanoma at an early stage appears especially important in an immunosuppressed population.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962173.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


27. Gligorov J, Cals L, Tournigand C, Merad Z, Dutel J, Selle F, Zeghib N, Chibaudel B, Cvitkovic F: Gemcitabine-oxaliplatin combination (SEGEMOX) in anthracycline (A) and taxanes (T) pretreated metastatic breast cancer (MBC): Results from the GERCOR-SEGEMOX phase II trial. J Clin Oncol; 2009 May 20;27(15_suppl):1108

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • : 1108 Objectives: To evaluate efficacy and safety of SEGEMOX regimen for previously A and T pre-treated MBC patients.
  • METHODS: Forty-five women with MBC not eligible for A and/or T chemotherapy were enrolled on SEGEMOX study.
  • Visceral metastases were dominant site of disease (44% liver; 36% lung; 44% bone).
  • After a median of 7.7 cycles (3.5 months of treatment); the overall response rate (ORR) is 38% [95%CI; 23%-51%] [1 CR (2.2%) and 16 PR (35.6%)]; 33% of stable disease [95%CI; 17%-43%], 24.4% progressive disease with a clinical benefit (CB) of 71% [95%CI; 57%-85%].
  • The median progression free survival (PFS) is 7.1 months for responders and 4.8 months for patients with stable disease.
  • The all population median overall survival (OS) is 21.4 months with 22.7 months MOS for responders.
  • The most frequent non hematologic toxicities were represented by grade 3 peripheral neuropathy (Levi Scale) in 11.4% of the patients and grade 2 alopecia in 11.4%.
  • For the subgroup of hormone receptor negative MBC (n = 12) the ORR is 33% [95%CI; 2%-64%], CB 50% [95%CI; 16%-73%], PFS of 2.8 months and MOS of 12 months.
  • CONCLUSIONS: The SEGEMOX combination has relevant activity in A and T not eligible MBC patients, with a manageable toxicity profile.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962168.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


28. Pennell NA, Videtic GM, Murthy S, Mason D, Rice TW, Mazzone P, Samsa J, Rich T, Shapiro M, Mekhail T: A phase I/II trial of perioperative paclitaxel (P), carboplatin (C), and erlotinib (E) with concurrent accelerated hyperfractionated radiation (HFRT) followed by maintenance E for stage III non-small cell lung cancer (NSCLC). J Clin Oncol; 2009 May 20;27(15_suppl):7557

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A phase I/II trial of perioperative paclitaxel (P), carboplatin (C), and erlotinib (E) with concurrent accelerated hyperfractionated radiation (HFRT) followed by maintenance E for stage III non-small cell lung cancer (NSCLC).
  • Non-progressors underwent resection followed by the same CRT regimen and 2 years of mE (150mg).
  • The primary endpoint of the phase I portion was the maximum tolerated dose (MTD) of E given with CRT; and for the phase II was safety and tolerability.
  • At a median follow-up of 36.5 mos the median PFS is 41.8 mos (95% CI 9.3-not yet reached).
  • Pts downstaged to pN0-1 vs those with persistent pN2-3 had a median PFS of 41.8 vs 18.1 mos (p=0.11).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963345.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


29. Franklin WA, Gandara DR, Kim ES, Herbst RS, Moon J, Redman MW, Olsen C, Hirsch FR, Mack P, Kelly K: SWOG S0342 and S0536: Expression of EGFR protein and markers of epithelial-mesenchymal transformation (EMT) in cetuximab/chemotherapy-treated non-small cell lung cancer (NSCLC). J Clin Oncol; 2009 May 20;27(15_suppl):11076

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] SWOG S0342 and S0536: Expression of EGFR protein and markers of epithelial-mesenchymal transformation (EMT) in cetuximab/chemotherapy-treated non-small cell lung cancer (NSCLC).
  • There was a trend for overall survival and EGFR level at each cutpoint in S0536 but the results did not achieve statistical significance (15 vs 11 mos, p=0.14; 15 vs 11 mos, p=0.20 and 14 mos vs not reached, p=0.10, respectively).
  • Vimentin (6 positive pts) was associated with a shorter PFS, HR=2.60 (1.10-6.14), p=0.03.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963196.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


30. Haas N, Manola J, Pins M, Liu G, McDermott D, Nanus D, Heath E, Wilding G, Dutcher J: ECOG 8802: Phase II trial of doxorubicin (Dox) and gemcitabine (Gem) in metastatic renal cell carcinoma (RCC) with sarcomatoid features. J Clin Oncol; 2009 May 20;27(15_suppl):5038

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We evaluated Dox/Gem in these pts with locally advanced or metastatic disease to confirm previous activity of this regimen in a single institution trial.
  • METHODS: Pts received Dox 50mg/m<sup>2</sup> IV push and Gem 1500mg/m<sup>2</sup> IV over 30 minutes every 2 weeks (with G-CSF 5 mcg/kg/d days 2 or 3 to 10 or pegfilgrastim 6 mg day 2) until disease progression or unacceptable toxicity.
  • Pts were mostly male (81%), with cT3/T4 (68%), node negative (61%), M1 (58%) disease at diagnosis and ECOG PS 0-1.
  • 9 patients had stable disease.
  • Two pts are alive without progression (1 with a PFS of 2.5 years), 1 is alive with progression, and 35 patients have died.
  • Median PFS is 3.5 months (95% CI 2.8-5.2 mos).
  • Median OS is 8.8 mos (6.1-11.1 mos).
  • CONCLUSIONS: Dox/Gem met efficacy criteria in RCC with sarcomatoid features.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962934.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


31. Villaflor VM, Kanteti R, Watson SM, Karrison T, Vokes EE, Salgia R: Response and survival in African American (AA) patients (pts) with non-small cell lung cancer (NSCLC) treated with erlotinib (E). J Clin Oncol; 2009 May 20;27(15_suppl):e19006

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Response and survival in African American (AA) patients (pts) with non-small cell lung cancer (NSCLC) treated with erlotinib (E).
  • EGFR activating mutations correlate with adenocarcinoma histology, non-smoking history, female gender, and Asian ethnicity.
  • It has also been determined that EGFR and met can crosstalk, and serve as potential mechanism of resistance in NSCLC.
  • We will correlate these data with EGFR mutation and c-Met expression/mutations/amplifications for markers of NSCLC.
  • Overall response rate of 13.6% (6-PR, 16-SD, 18-progessive disease, and 4 patients lost to follow up).
  • The PFS was 4.0 months; 95% CI: (2.5-6.6 mos) and overall survival 8.6 mos; 95% CI: (7.2-30.9 mos).
  • EGFR mutations and c-Met analysis will be provided by ASCO meeting in May 2009.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962520.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


32. Vishnu P, Jasti P, Ding L, Heilbrun LK, Venkatramanamoorthy R, LoRusso PM, Heath EI: Retrospective study of phase I clinical trials participation in patients at least 65 years of age at Karmanos Cancer Institute (KCI), Wayne State University, Detroit, Michigan. J Clin Oncol; 2009 May 20;27(15_suppl):e20626

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The primary objective of this study was to describe the demographics, treatment, toxicity, and overall survival (OS) of all patients ≥ 65 years who presented to the Phase I clinical trials service at KCI between 1995-2005.
  • RESULTS: 216 patients met the study criteria.
  • 66% of patients had a history of cardiovascular disease but renal, liver, hematological diseases were found in less than 7% of patients at baseline.
  • The median OS for PC, PE, and PT was 3.9 mos, 2.2 mos, and 8.4 mos, respectively (p < 0.001 between any pair).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961597.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


33. Gutierrez M, Murgo AJ, Allen D, Turkbey I, Gardner ER, Trepel J, Chen H, Giaccone G, Doroshow JH, Kummar S: Phase I study of vandetanib (V) and bevacizumab (B) combination therapy evaluating the VEGF and EGF signal transduction pathways in adults with solid tumors and NHL. J Clin Oncol; 2009 May 20;27(15_suppl):3522

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • DIAGNOSIS: pancreatic-1, NSCLC-1, colorectal-3, peritoneal mesothelioma-1, melanoma-1, NHL-1, jejunal adenocarcinoma (JAC)-1.
  • Partial Response (PR) was achieved in 2 pts (pancreatic 14 mos + and JAC 6 mos); disease stabilization in 5 pts (4 mos +).
  • CONCLUSIONS: We decided not to escalate beyond DL 2 due to the gr 2-3 toxicities observed with chronic therapy.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961325.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


34. Sternberg CN, Szczylik C, Lee E, Salman PV, Mardiak J, Davis ID, Pandite L, Chen M, McCann L, Hawkins R: A randomized, double-blind phase III study of pazopanib in treatment-naive and cytokine-pretreated patients with advanced renal cell carcinoma (RCC). J Clin Oncol; 2009 May 20;27(15_suppl):5021

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: Pts (N = 400 planned) with clear cell advanced RCC and measurable disease with no prior treatment or 1 prior cytokine-based treatment, were stratified and randomized (2:1) to pazopanib 800 mg QD or placebo.
  • The primary endpoint was progression-free survival (PFS).
  • The study had ≥ 90% power to detect an 80% improvement in PFS and a 50% improvement in OS, by stratified log-rank tests with α = 0.025 one-sided.
  • Pts received continuous treatment until disease progression (PD), death or unacceptable toxicity.
  • PFS was significantly prolonged with pazopanib in the overall study population (9.2 vs 4.2 mos; HR: 0.46; 95% CI: 0.34, 0.62; p < 0.0000001), in treatment naïve pts (11.1 vs 2.8 mos; HR: 0.40; 95% CI: 0.27, 0.60; p < 0.0000001), and in cytokine-pretreated pts (7.4 vs 4.2 mos; HR: 0.54; 95% CI: 0.35, 0.84; p < 0.001).
  • Median duration of exposure was 7.4 mos (pazopanib) and 3.8 mos (placebo).
  • The most common laboratory abnormality was ALT elevation (53%; 10% Gr 3; 2% Gr 4).
  • (2) is the inventor of a unique technology or treatment being evaluated in the clinical trial; or (3) is involved in international clinical oncology research and has acted consistently with recognized international standards of ethics in the conduct of clinical research.
  • Abstracts for which authors requested and have been granted an exception in accordance with ASCO's Policy are designated with a caret symbol (^) in the Annual Meeting Proceedings.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962920.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


35. Boccardo F, Rubagotti A, Guglielmini P, Sismondi P, Farris A, Amadori D, Agostara B, Gambi A, Catalano G, Faedi M: Epirubicin (E) followed by cyclophosphamide, methotrexate, 5-fluorouracil (CMF) versus paclitaxel (T) followed by epirubicin and vinorelbine (EV) in patients (pts) with high-risk operable breast cancer. J Clin Oncol; 2009 May 20;27(15_suppl):e11521

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • After CT, tamoxifen (plus a LH-RH analog in menstruating women ) was given for 5 years to all HOR+ pts.S was the primary end-point.
  • RESULTS: At 82 mos median f-up, S and RFS did not differ significantly between groups (7-yr S: E-CMF:76%,T- EV:74%;adjust.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964621.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


36. Heymach J, Jonasch E, Wang X, Du DZ, Yan S, Xu L, Herynk MH, McKee KS, Tran HT, Tannir NM, Zurita AJ: A cytokine and angiogenic factor (CAF) plasma signature for selection of sorafenib (SR) therapy in patients (pts) with metastatic renal cell carcinoma (mRCC). J Clin Oncol; 2009 May 20;27(15_suppl):5114

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The primary objective of this analysis was to establish a CAF signature based on a set of individual markers at BL with a significant and differential impact on the association between treatment arm and PFS.
  • Pts with high OPN benefitted more from single agent SR (7.74 vs. 3.93 mos for the combination; p = 0.007), but no differences were found for those with low OPN.
  • Lower than median on-treatment increases in sCA9 (D28, p = 0.01) and GRO-alpha (D56, p = 0.04) on SR only were also associated with a better outcome.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964391.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


37. Rice K, Peay K, Hudak J, Elsamanoudi S, Travis J, Lockhart R, Jennifer C, Black L, Hogue S, Brassell S: Factors for choosing prostate cancer treatment and resulting impact on health related quality of life. J Clin Oncol; 2009 May 20;27(15_suppl):9601

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The instruments are the EPIC, EPIC Demographic, and the MOS Short-Form 36.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963832.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


38. Caffo O, Fellin G, Graffer U, Mussari S, Caldara A, Murgia V, Valduga F, Tomio L, Galligioni E: Cisplatin (C) and gemcitabine (G) chemotherapy with concurrent irradiation (XRT), for the conservative treatment of invasive transitional bladder cancer (ITBC) patients: Clinical outcome and long-term follow-up in a monoinstitutional experience. J Clin Oncol; 2009 May 20;27(15_suppl):e16081

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In a dose finding trial, conducted in our hospital on ITBC patients using C and G with concurrent XRT, after maximum transurethral resection (TUR), the maximum tolerated dose of G was 400 mg/sqm (IJROBP 2003).
  • We are presenting the long-term clinical outcome of the 16 patients involved in the dose-finding trial, together with that of the 9 pts enrolled in the phase II study.
  • In dose finding study G was given weekly from 200 to 500 mg/sqm: since unacceptable toxicity was observed in 2 cases (one death for toxicity) at the higher dose level, the recommended G dose for phase II trial was 400 mg/sqm on day 1,8 q 21 for 2 courses together with C and XRT.
  • A cystoscopic re-evaluation was scheduled 6-8 weeks after treatment.
  • RESULTS: Except the pt died during treatment for toxicity, all the remaining 24 pts were microscopically disease free at cystoscopic re-evaluation.
  • Seven local and 2 distant relapses have been observed so far, at a median follow-up of 66 mos.
  • Presently, 16 pts (67%) is alive and disease-free, with 1 patient died for lung cancer.
  • All pts alive have retained their bladder, with a normal organ function, in absence of any relevant long-term toxicity.
  • Considering the 100% of complete response observed, this combination could be of interest to explore a possible enhancement of the disease control of C plus XRT, that is today the treatment of choice in the conservative therapy of ITBC.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963102.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


39. Vogelzang NJ, Hutson TE, Samlowski W, Somer B, Richey S, Alemany C, Loesch D, Richards P, Gardner L, Sportelli P: Phase II study of perifosine in metastatic renal cell carcinoma (RCC) progressing after prior therapy (Rx) with a VEGF receptor inhibitor. J Clin Oncol; 2009 May 20;27(15_suppl):5034

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II study of perifosine in metastatic renal cell carcinoma (RCC) progressing after prior therapy (Rx) with a VEGF receptor inhibitor.
  • In a prior trial, 15 RCC patients (pts) were enrolled in a randomized dose finding study, 9 were evaluable for response and 3 (33%) had a partial response (PR).
  • Thus phase II trials were begun for pts who had been treated with one prior VEGFr inhibitor (Group A) or with a prior VEGFr inhibitor and prior mTOR inhibitor (Group B).
  • METHODS: To measure the objective response rate (RECIST) and PFS to single agent perifosine (100 mg qhs with food) after 3 mos of Rx; Prior Rx with vaccine therapy, bevacizumab and/or cytokines was permitted.
  • Normal organ/marrow function was required.
  • Median age 64 (range 46-80) and 36 were male; Median prior Rx was 2 (range 1 - 5); Clear cell = 37, non clear cell = 6, data n/a = 3.
  • CONCLUSIONS: Perifosine, similar to mTOR inhibitors, appears to have clinical benefit in mRCC as reflected by the PR rate and a 15 wk median overall PFS.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962937.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


40. Kobayashi K, Inoue A, Maemondo M, Sugawara S, Isobe H, Oizumi S, Saijo Y, Gemma A, Morita S, Hagiwara K, Nukiwa T: First-line gefitinib versus first-line chemotherapy by carboplatin (CBDCA) plus paclitaxel (TXL) in non-small cell lung cancer (NSCLC) patients (pts) with EGFR mutations: A phase III study (002) by North East Japan Gefitinib Study Group. J Clin Oncol; 2009 May 20;27(15_suppl):8016

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] First-line gefitinib versus first-line chemotherapy by carboplatin (CBDCA) plus paclitaxel (TXL) in non-small cell lung cancer (NSCLC) patients (pts) with EGFR mutations: A phase III study (002) by North East Japan Gefitinib Study Group.
  • Pts having sensitive EGFR mutations, measurable site(s), ECOG PS 0-1, age of 20-75 years, and no prior chemotherapy were randomized (1:1 ratio; balanced for institution, sex, and stage) to receive Arm A: gefitinb (250 mg/ day) orally, or Arms B: CBDCA AUC 6 and TXL 200mg/m2 in 21-day cycles until disease progression.
  • The primary endpoint was PFS, and the sample size was calculated to be 320 in total (alpha=5%, power=80%) to confirm the superiority of Arm A (hazard ratio = 0.69).
  • Their characteristics were well balanced between arms: median age=65 years; 64% female; 77% Stage IV; 93% adenocarcinoma, 61% non-smoker.
  • There were several differences in toxicities between Arm A and Arm B (grade 4 neutropenia: 1% vs. 29%, grade 3-4 liver dysfunction: 24% vs. 1%, grade 3 neuropathy: 0% vs. 5%, respectively, p<0.01).
  • Furthermore, there were no interstitial lung disease and no toxic deaths in both arms.
  • Analyzing both arms together, preliminary response rate and PFS of the 155 pts were 53.7% and 6.5 mos, respectively.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962807.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


41. Krop IE, Burris HA, Rugo H, O'Shaughnessy J, Vogel CL, Amler L, Strauss A, Wong EK, Klencke B, Pippen J: Quantitative assessment of HER2 status and correlation with efficacy for patients (pts) with metastatic breast cancer (MBC) in a phase II study of trastuzumab-DM1 (T-DM1). J Clin Oncol; 2009 May 20;27(15_suppl):1003

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RESULTS: As of August 29, 2008, 112 pts had enrolled; 107 were efficacy-evaluable pts with median 4.4 mos follow-up.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27960714.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


42. Heng DY, Xie W, Regan MM, Cheng T, North S, Knox JJ, Kollmannsberger C, McDermott D, Rini BI, Choueiri TK: Prognostic factors for overall survival (OS) in patients with metastatic renal cell carcinoma (RCC) treated with vascular endothelial growth factor (VEGF)-targeted agents: Results from a large multicenter study. J Clin Oncol; 2009 May 20;27(15_suppl):5041

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The median (m) OS was 22 months (95% CI: 20.0-24.8) with a median follow-up of 25 months.
  • Four of the five PFs previously identified by MSKCC were independent predictors of short survival, including hemoglobin below the lower limit of normal (LLN) (p < 0.0001), corrected calcium above the upper limit of normal (ULN) (p = 0.0006), Karnofsky performance status <80% (p < 0.0001) and time from initial diagnosis to initiation of therapy ULN (pULN (p = 0.012) were independent adverse PFs.
  • Patients were assigned one point for each poor PF and were segregated into three risk categories: favorable-risk (0 PFs, n = 133) median OS (mOS) 37.0 months; intermediate-risk (1 - 2 PFs, n = 292) mOS 28.5 months; and poor-risk (3-6 PFs, n = 139) mOS 9.4 months (log rank p < 0.0001).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962941.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


43. Hartmann JT, Aschoff P, Dittmann H, Lichy M, Mayer F, Reischl G, von Weyhern C, Kanz L, Claussen CD, Pfannenberg C: The value of PET/CT with 18F-FLT and 18F-FDG in the management of metastatic germ cell tumors (GCT): A pilot study. J Clin Oncol; 2009 May 20;27(15_suppl):e16142

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The results were validated by histopathology of resected residual masses after CTh in 7 pts or by clinical follow-up for at least 6 mos in 4 pts.
  • Presence of necrosis was judged as responder, as well as CR/PRm- within a minimum progression-free interval (PFI) of 6 mos.
  • RESULTS: 8 out of 11 pts had a PFI > 6 mos (range, 206-1337 days).
  • SUVavg decrease in early response FDG monitoring was 64% in responders and 60% in non-responders (p = 0.8), as well as 57% vs. 48% for FLT (p = 0.5), respectively, and 85% vs. 72% (FDG, p = 0.1) and 67% vs. 65% (FLT, p = 0.8) in the final monitoring.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963433.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


44. Mancuso AP, Donato De Paola E, Catalano A, Calabrò F, Messina C, Zivi A, Cerbone L, Vigna L, Caristo R, Sternberg CN: Phase II dose escalation study of sorafenib in patients with metastatic renal cell carcinoma (mRCC) who have had prior treatment with VEGFR-TKI antiangiogenic treatment. J Clin Oncol; 2009 May 20;27(15_suppl):e16027

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Pts with no progressive disease (evaluated at 12 weeks) continued to receive Sorafenib at the standard dose, while progressive pts received an increasing dose (600 mg BID) with early disease restaging after 4 weeks.
  • RESULTS: 18 pts were entered; baseline characteristics: PS 0-1: 94%; median age 62 years (41-82); nephrectomy: 100%; surgery for metastatic disease: 28%, clear-cell 78%, papillary-cell 16%, sarcomatoid 6%.
  • Overall, 72% of pts had disease control without significant correlations between response to prior therapy and hypertension.
  • 14 pts had progression free survival (PFS) of 4.3 months (mos).
  • 4 pts are still in treatment with a median PFS > 8 mos.
  • Of 6 pts in which the dose was escalated, 3 benefitted with a PFS of > 3 mos.
  • Other hematological and non-hematological toxicities were g1 with a frequency < 15%.
  • In progressive patients, treatment with a higher dose could be a valid option.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962966.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


45. Cerbone L, Van Ginderdeuren R, Van den Oord J, Fieuws S, Spileers W, Van Eenoo L, Wozniak A, Sternberg CN, Schöffski P: Clinical presentation, pathological features, and natural course of metastatic uveal melanoma (MUM) as an orphan and commonly fatal disease. J Clin Oncol; 2009 May 20;27(15_suppl):e20005

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical presentation, pathological features, and natural course of metastatic uveal melanoma (MUM) as an orphan and commonly fatal disease.
  • : e20005 Background: Uveal melanoma (UM) is a rare disease characterized by an unpredictable course and variable outcome ranging from cure by local treatment to the occurrence of untreatable metastasis.
  • RESULTS: The med. age at diagnosis of UM was 58 yrs (range 30-94).
  • MUM was more common in women (F:M ratio 48:28) and independent from the side of the primary tumor (left vs. right eye).
  • Synchronous metastasis was found in 9% of cases, all others had metachronous disease after a med. interval of 40 mos (range, 7-420).
  • Statistical analysis failed to identify predisposing factors for MUM with the exception of a significant negative correlation between age at diagnosis of UM and time until metastatic disease (Spearman ρ = -0.4, p<0.001).
  • The most frequent sites were liver (96%), lung (23%), subcutaneous (13%), bone (11%) and brain (3%).The med.
  • OS from diagnosis of UM was 46 mos (range, 2-182), and 4,5 mos after diagnosis of metastasis (range, 1-128).
  • CONCLUSIONS: In this orphan disease with female predominance metastasis occurs late, is mainly found but not confined to the liver, and is associated with high morbidity, as >1/3 of pts do not qualify for further therapy.
  • Advances in MUM can only be achieved by networking of sites interested in this tumor with systematic collection of data and tissue to improve our understanding of the molecular biology of the disease.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962598.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


46. Urba S, Schneider BJ, Hayman JA, Orringer M, Chang A, Pickens A, Pan C, Lee J, Foster J, Merajver S: Preoperative chemoradiation and postoperative adjuvant tetrathiomolybdate for patients with resectable esophageal cancer. J Clin Oncol; 2009 May 20;27(15_suppl):e15504

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • 13 pts completed the full 24 mos of treatment, 12 completed 10-23 mos, 15 completed 2-8 mos, and 8 completed only 1 month or less.
  • 27 pts have had disease recurrence, the majority (23 of the 27) of which was distant.
  • Current status of pts with median follow-up time of 55 months: 25 alive and disease-free, 1 alive with disease, and 43 have died.
  • Disease-free survival and overall survival are promising when compared to historical controls treated with a very similar chemoradiation regimen without TM in the past at the University of Michigan.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962224.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


47. Markowicz S, Nowecki ZI, Rutkowski P, Lipkowski AW, Jakubowska-Mucka A, Switaj T, Biernacka M, Misicka A, Walewski JA, Ruka W: Adjuvant vaccination with melanoma antigen pulsed dendritic cells (DCs) in stage III melanoma patients. J Clin Oncol; 2009 May 20;27(15_suppl):9039

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adjuvant vaccination with melanoma antigen pulsed dendritic cells (DCs) in stage III melanoma patients.
  • : 9039 Background: This is a pilot study evaluating of high-risk melanoma patients (pts) treated with peptide-DC vaccine after lymphadenectomy (LND).
  • DC vaccination was designed to induce the immune response against melanoma antigens in melanoma pts who remain at high risk of dissemination after LND.
  • METHODS: DCs were generated from the bone marrow with the use GM-CSF, SCF, FLT3-L and TNFa or from peripheral blood adherent monocytes with GM-CSF and IL-4.
  • DCs pulsed with HLA-A2-binding TYR, MART-1 and gp100 peptides and/or HLA-A1-binding MAGE-1, MAGE-3 peptides, tumor lysate if available, or with tracer antigen keyhole limpet hemocyanin (KLH), were injected sc 9 times within 8 months (mos).
  • Boost injections were performed after 12 and 24 mos.
  • RESULTS: HLA-A2<sup>+</sup>, -A1<sup>+</sup> or -A3<sup>+</sup> melanoma pts (n=22), stage III, N1b-N3, enrolled between Sept.
  • Cutaneous delayed type hypersensitivity (DTH) to melanoma peptides was induced in 12 of 22 pts.
  • At least one of these responses to melanoma antigens was elicited in 17 of 22 pts.
  • Nine vaccinated pts are free of disease, and 1 is stable by Dec.
  • 2008 (follow up is 58-76 mos after LND).
  • CONCLUSIONS: The DC/peptide vaccine elicited immune responses to melanoma antigens.
  • Vaccinated pts had clinically substantially longer overall survival (OS) and disease free survival (DFS) than matched control.
  • OS was associated with the immune responsiveness to melanoma antigens and to KLH.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962116.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


48. Richardson PG, Chanan-Khan A, Lonial S, Krishnan A, Carroll M, Alsina M, Albitar M, Berman D, Kaplita S, Anderson K: Tanespimycin plus bortezomib in patients with relapsed and refractory multiple myeloma: Final results of a phase I/II study. J Clin Oncol; 2009 May 20;27(15_suppl):8503

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tanespimycin plus bortezomib in patients with relapsed and refractory multiple myeloma: Final results of a phase I/II study.
  • METHODS: 72 patients (pts) with relapsed/refractory MM received 0.7 - 1.3 mg/m<sup>2</sup> Bz as IVB followed by 1-hr infusion of 100 -340 mg/m<sup>2</sup> Tan on days 1, 4, 8,11 q 21d, with 42 pts receiving the highest dose of both drugs as part of a phase II expansion.
  • RESULTS: Of 72 pts, 72% had IgG subtype with a median age of 60 yo.
  • Median time since MM diagnosis was 50 mos with median of 5 (1-15) prior regimens.
  • 58 pts with measurable disease were treated at 1 or 1.3 mg/m<sup>2</sup> Bz.
  • Median duration of response (DOR) for all pts with response (n=14) was 10.7 mos, including 3 Bz-refractory pts who had durable PR through mos 12, 22 and 28.
  • 3 other pts remain in response through 24 mos.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27960855.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


49. Cortes JE, Khoury HJ, Corm S, Nicolini F, Schenk T, Jones D, Hochhaus A, Craig AR, Humphriss E, Kantarjian H, Omacetaxine 202 Study Group: Subcutaneous omacetaxine mepesuccinate in imatinib-resistant chronic myeloid leukemia (CML) patients (Pts) with the T315I mutation: Data from an ongoing phase II/III trial. J Clin Oncol; 2009 May 20;27(15_suppl):7008

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Subcutaneous omacetaxine mepesuccinate in imatinib-resistant chronic myeloid leukemia (CML) patients (Pts) with the T315I mutation: Data from an ongoing phase II/III trial.
  • : 7008 Background: Omacetaxine (OM), a first-in-class cetaxine shows clinical activity against Ph+ CML with a mechanism independent of tyrosine kinase inhibition.
  • RESULTS: 66 pts (39 chronic [CP], 16 accelerated [AP] and 11 blast phase [BP]) have been enrolled.
  • Median disease duration is 58 mos.
  • OM is well tolerated with transient myelosuppression as the primary toxicity.
  • Grade 3/4 non-hematologic events are diarrhea (2%) and fatigue (4%).
  • CONCLUSIONS: Omacetaxine in T315I+ CML Pts results in de-selection of the T315I clone and induces hematologic and cytogenetic responses.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961380.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


50. Edelman MJ, Belani CP, Socinski MA, Ansari R, Obasaju CK, Monberg MJ, Chen R, Treat J: Incidence and outcomes associated with brain metastases (BM) in a three-arm phase III trial of gemcitabine in combination with carboplatin (GC) or paclitaxel (GP) versus paclitaxel plus carboplatin (PC) for advanced non-small cell lung cancer (NSCLC). J Clin Oncol; 2009 May 20;27(15_suppl):8076

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Incidence and outcomes associated with brain metastases (BM) in a three-arm phase III trial of gemcitabine in combination with carboplatin (GC) or paclitaxel (GP) versus paclitaxel plus carboplatin (PC) for advanced non-small cell lung cancer (NSCLC).
  • Analyses of pts with lung cancer from the 1970s and 1980s indicated that the incidence of BM at the time of diagnosis was approximately 10%.
  • Cycles were repeated every 21 d up to 6 cycles or disease progression.
  • Among pts with (N=194) and without (N=941) BM, response rates=28.9% and 29.1%, median survival = 7.7 mos (95% CI: 6.7, 9.3) and 8.6 mos (95% CI: 7.9, 9.5), and median time to progression = 4.3 mos (95% CI: 3.4, 5.6) and 4.6 mos (95% CI: 4.2, 5.1), respectively.
  • Median survival among pts with BM was 7.6 mos for GC (N=66, 95% CI: 6.3, 10.1), 8.2 mos for GP (N=64, 95% CI: 4.6, 10.5), and 7.7 mos for PC (N=64, 95% CI: 6.1, 10.2). CONCLUSIONS:.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962650.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


51. Kantarjian H, Giles F, Bhalla K, Pinilla J, Larson RA, Gattermann N, Ottmann OG, Gallagher NJ, Baccarani M, leCoutre P: Nilotinib in chronic myeloid leukemia patients in chronic phase (CML-CP) with imatinib (IM) resistance or intolerance: Longer follow-up results of a phase II study. J Clin Oncol; 2009 May 20;27(15_suppl):7029

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Nilotinib in chronic myeloid leukemia patients in chronic phase (CML-CP) with imatinib (IM) resistance or intolerance: Longer follow-up results of a phase II study.
  • METHODS: Primary endpoint was major cytogenetic response (MCyR).
  • RESULTS: CML-CP pts (n = 321, 70% IM-resistant, 30% IM-intolerant with resistance) with a minimum follow-up of 19 months (mos) were evaluated; 72% were treated with ≥600 mg/day IM prior to enrollment.
  • Median duration of prior IM treatment was 32 (<1-94) mos.
  • 59% achieved an MCyR (2.8 mos median time to MCyR; 56% in IM-resistant, and 65% in IM-intolerant pts), including 73% of pts with a baseline CHR and 44% achieved a CCyR (41% in IM-resistant; 51% in IM-intolerant pts).
  • Responses were durable, with 78% pts maintaining MCyR at 24 mos.
  • Estimated OS rate was 88% at 24 mos.
  • Gr 3/4 non-hematologic AEs were infrequent: rash, headache, and diarrhea occurred in 2% of pts.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961402.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


52. Bhatnagar B, Tiu RV, Gondek LP, O'Keefe C, Huh J, Advani AS, Sekeres MA, Maciejewski JP: Use of SNP-array-based karyotyping for cytogenetic prognostication in unclassified cases of myelodysplasia and associated overlap disorders. J Clin Oncol; 2009 May 20;27(15_suppl):7016

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • : 7016 Background: Myeloproliferative disorders (MPD) and myelodysplastic syndromes (MDS) often have overlapping features resulting in unclassifiable cases (MDS-U and MDS/MPD-U).
  • METHODS: MDS-U (N = 17) and MDS/MPD-U (N = 61) patients were selected from an MDS database (N = 720, median age = 76, median follow-up = 42 mos).
  • MDS/MPD-U and MDS-U patients had similar OS and EFS (OS = 42 vs. 45 mos, p = 0.13; EFS = 42 vs. 45 mos p = 0.63).
  • Overall, patients with new SNP-A lesions had worse OS and EFS (OS = 41 mos vs NR, p = 0.07; EFS = 32 vs 112 mos, p = 0.07).
  • This technology will be helpful in refining diagnosis based on characteristic recurrent chromosomal lesions including UPD.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961389.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


53. Smith MR, Ellis G, Saad F, Tammela T, Bone H, Egerdie B, Ke C, Jun S, Dansey R, Goessl C: Effect of denosumab on bone mineral density (BMD) in women with breast cancer (BC) and men with prostate cancer (PC) undergoing hormone ablation therapy. J Clin Oncol; 2009 May 20;27(15_suppl):9520

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effect of denosumab on bone mineral density (BMD) in women with breast cancer (BC) and men with prostate cancer (PC) undergoing hormone ablation therapy.
  • However, these treatments increase bone resorption, leading to bone loss and fractures.
  • RANKL is a key mediator of osteoclast-mediated bone resorption.
  • METHODS: Two trials were conducted: a 24-mo BC study and a 36-mo PC study.
  • Postmenopausal women with low BMD receiving AI therapy for nonmetastatic BC and men receiving ADT for nonmetastatic PC (with low BMD or history of osteoporotic fracture if < 70 yrs) were randomized to receive placebo or denosumab 60mg subcutaneously every 6 mos.
  • The primary endpoint was % change from baseline in lumbar spine (LS) BMD at 12 mos for the BC study and at 24 mos for the PC study.
  • Herein, we present changes in BMD at 24 mos at LS, total hip (TH), and 1/3 radius from both studies.
  • Power calculations were based on enrollment of at least 208 patients in the BC study (for primary endpoint only) and 1226 in the PC study (for primary and key secondary endpoints).
  • RESULTS: Denosumab increased BMD of the LS, TH, and 1/3 radius compared with placebo at 24 mos in both pt populations ( Table ).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964507.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


54. Hohenberger P, Oladeji O, Licht T, Dimitrakopoulou-Strauss A, Jakob J, Pink D, Schwarzbach M, Ströbel P, Reichardt P, Wardelmann E: Neoadjuvant imatinib and organ preservation in locally advanced gastrointestinal stromal tumors (GIST). J Clin Oncol; 2009 May 20;27(15_suppl):10550

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: 36 patients with biopsy proven GIST (23 f, 13 m, median age 58 (27-85) yrs, 31 primary tumors, 5 local recurrences) of the esophagus/EGJ (n=5), stomach (n=17), duodenum (n=2), small bowel (n=3), or rectum (n=9) were treated with imatinib 400mg/d for 6 mos. preop.
  • Extent of surgery, local outcome, morbidity and response to therapy were analyzed; median follow-up is 22 mos.
  • RESULTS: Median treatment duration was 11 mos. (range 2-31 mos).
  • 33 pts. completed the treatment schedule, two died from unrelated disease, another one had to be operated for tumor rupture.
  • Histologically, one pCR and 11 near CR/good PRs were found.
  • Two local recurrences were detected at 31 and 44 mos. postop.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963946.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


55. Blinder VS, Patil S, Diamant A, Thind A, Maly R: Employment status among low-income Caucasian and Latina breast cancer survivors. J Clin Oncol; 2009 May 20;27(15_suppl):6612

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: This is a prospective, longitudinal study of low-income, underserved breast cancer survivors who spoke English or Spanish, did not have metastatic disease, and were enrolled in the Medi-Cal Breast and Cervical Cancer Treatment Program.
  • We interviewed survivors at 6 mos., 18 mos., and 3 yrs. after diagnosis to assess changes in employment status.
  • The impact of independent variables including ethnicity, employment at diagnosis, job type, age, health status, and education was assessed using chi-square tests.
  • RESULTS: 666 survivors completed surveys at both 6 mos. and 3 yrs; 65% were Latina.
  • At diagnosis, 51% of Latinas and 59% of Caucasians were employed (p = 0.07), and among these, Latinas were less likely to be working at 6 and 18 mos. than Caucasians (27% vs. 47% at 6 mos., p = 0.002 and 45% vs. 59% at 18 mos., p = 0.026).
  • Job type at diagnosis was associated with RTW.
  • CONCLUSIONS: Employed low-income Latinas and Caucasians appear to follow different RTW trajectories after breast cancer, with fewer Latinas working at 6 and 18 mos.
  • Differences exist in job type between these populations; Caucasians have greater variation in job type and a trend toward greater likelihood of changing job type after breast cancer.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961765.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


56. Carducci MA, Armstrong DK, Collins C, Wang T, Schaefer S, Ermisch S, Musib LC, Nicol S, Thornton DE, Zhang Z: Phase I study of enzastaurin (ENZ) and bevacizumab (BV) in patients with advanced cancer: Safety, pharmacokinetics (PK), and response assessment. J Clin Oncol; 2009 May 20;27(15_suppl):3517

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • DLT was defined as C1: Grade (G)4 neutropenia ≥7 days, febrile neutropenia, G3 thrombocytopenia with bleeding or G4 thrombocytopenia; G3/G4 non-hematological toxicities, and toxicities associated with BV.
  • Nine of 43 pts (21%) had a response (CR, PR), 6 responses were in the ovarian subset (29%).
  • Median time to progression was 3.9 mos (range 0-19.2 mos) and 7.7 mos for ovarian pts (range 0.3-19.2 mos).
  • Overall, 43% remained on study without disease progression for >6 mos (51% of ovarian pts remained on study for >6 mos).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961299.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


57. Hussain A, Onukwugha E, Seal B, Mullins CD: Visit and treatment patterns over time among elderly patients (pts) with M1 prostate cancer (PC): An analysis using SEER-Medicare. J Clin Oncol; 2009 May 20;27(15_suppl):5170

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The study included pts with a post-diagnosis visit to a urologist; pts who saw a MOH prior to the urologist visit were excluded.
  • Pts were grouped as 1) no MOH visit, 2) MOH visit w/in 3 mos of a urologist visit, 3) MOH visit => 3 mos after a urologist visit.
  • 2) timely (i.e. within 6 mos of diagnosis); and 3) delayed, i.e.
  • => 6 mos following the diagnosis.
  • CONCLUSIONS: Approximately one-third of patients with M1 disease and a post-diagnosis urologist visit also see a medical oncologist.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964511.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


58. Gerstner ER, Yip S, Wang DL, Louis DN, Iafrate AJ, Batchelor TT: MGMT methylation status may predict survival in elderly patients with newly diagnosed glioblastoma (GBM). J Clin Oncol; 2009 May 20;27(15_suppl):e13023

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The logrank test was used to compare mPFS and mOS in patients who had methylated (ME) MGMT vs. unmethylated (UN) MGMT.
  • ME was associated with a significantly prolonged mPFS and mOS as noted in the table below which also summarizes the characteristics of the study population.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962794.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


59. Dhodapkar MV, Bolejack V, Shaughnessy J, Matthews P, Pickering R, Qu P, Hoering A, Crowley J, Barlogie B, Southwest Oncology Group: Role of T-cell immunity to embryonal stem (ES) cell antigen SOX2 in the progression of myeloma. J Clin Oncol; 2009 May 20;27(15_suppl):8522

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • : 8522 Background: Clinical outcome in patients (pts) with asymptomatic plasma-proliferative disorders, monoclonal gammopathy of undetermined significance (MGUS) and asymptomatic myeloma (AMM), is highly variable.
  • There is a need to identify specific tumor or host related features that predict the risk of disease progression.
  • METHODS: Patients with MGUS/AMM were enrolled in a prospective observational clinical protocol (SWOG S0120).
  • The presence of T cell immunity to SOX2 in freshly isolated blood / marrow mononuclear cells was analyzed using an overlapping peptide library at study entry.
  • Immunity to SOX2 correlated with features of lower risk including serum-M component < 1.5 g/dL (p=0.008), marrow plasmacytosis < 10% (p<0.001) and normal serum free light chain ratio (p=0.01).
  • CONCLUSIONS: These data demonstrate in the context of a prospective trial that T cell immunity to stem cell genes strongly correlates with a reduced risk of progression to clinical myeloma.
  • These data point to SOX2 as a potential target for the prevention of disease progression in MGUS/AMM.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27960897.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


60. Gitlitz BJ, Davies AM, Belani CP, Argiris A, Ramalingam SS, Hoffman PC, Koczwas M, Groshen SG, Gandara DR: A phase II study of the halichondrin B analog, E7389, in patients (pts) with advanced non-small cell lung cancer (NSCLC) previously treated with a taxane. A California Consortium/University of Pittsburgh/University of Chicago NCI/CTEP sponsored trial. J Clin Oncol; 2009 May 20;27(15_suppl):8056

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A phase II study of the halichondrin B analog, E7389, in patients (pts) with advanced non-small cell lung cancer (NSCLC) previously treated with a taxane. A California Consortium/University of Pittsburgh/University of Chicago NCI/CTEP sponsored trial.
  • METHODS: Eligible pts included: histologically confirmed advanced NSCLC, previous treatment with platinum-based therapy and a taxane, no more than 2 prior regimens, measurable disease, Zubrod performance status ≤ 2.
  • TREATMENT: E7389 1.4 mg/m<sup>2</sup> intravenously over 1-2 minutes on day 1 and 8 of a 21 day schedule until disease progression or unacceptable toxicity.
  • Stable disease rate was 60% and 24% in TS and TR pts. respectively.
  • Median progression free survival (PFS) is 6.3 mos TS pts.
  • 95%CI (2.5-8.6 mos) and 1.2 mos TR pts.
  • 95%CI (1.1-4.1 mos).
  • Major toxicity included: 19 pts (46%) with grade 3 or 4 hematologic toxicity including only 1 episode of febrile neutropenia and 8 pts (20%) with grade 3 or 4 non-hematologic toxicity attributable to drug including: fatigue (1), dehydration (2), nausea (2), constipation (2).
  • CONCLUSIONS: E7389 was well tolerated with encouraging objective response, PFS and disease control rate in the TS cohort.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962869.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


61. Goodman LJ, Weston JK, Mukherjee A, Sperinde J, Paquet A, Williams S, Parry G, Bates M, Koestler W, Lipton A: Quantitative measurement of HER3 total protein (H3T) and association with clinical outcome in HER2-positive metastatic breast cancer patients treated with trastuzumab. J Clin Oncol; 2009 May 20;27(15_suppl):1021

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A previously reported H2T cutoff was used to sub-divide the patients into HER2-normal (N = 26, median TTP = 4.1 mos) and HER2-overexpressing (N = 55, median TTP = 11.1 mos, HR = 0.43, p = 0.0002) groups.
  • In the HER2-overexpressing group, high H3T expression, as defined by a positional scanning cutoff analysis, predicted shorter median time to progression (N = 25, median TTP = 6.1 mos) compared with low H3T expression (N = 30, median TTP = 13.1 mos, HR = 2.7, p = 0.0002).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961045.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


62. Onukwugha E, Mullins CD, Obeidat N, Seal B, Hussain A: The impact of docetaxel (D) in an older population of patients with advanced prostate cancer (PC): A simulation study using TAX327 and SEER Medicare data. J Clin Oncol; 2009 May 20;27(15_suppl):e16074

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • : e16074 Background: The survival benefit of D in treatment of hormone refractory PC (HRPC) has been established in the TAX327 trial, but it is unclear how this benefit would translate in a heterogeneous population.
  • This study sought to simulate the survival impact of D in a population of older pts with M1 PC on androgen deprivation therapy (ADT).
  • The simulated benefit was assessed at 12 mos and 24 mos post-diagnosis of M1 PC in SM pts.
  • Median survival was 15.7 mos (12.6 - 19) in the M arm and 18.9 mos [17 - 21.8] in the D3P arm (p = 0.03).
  • Median survival benefit of D was 3.2 mos based on Kaplan-Meier estimates and 2.4 mos using parametric curves in the TAX327 69+ group.
  • Following covariate-adjustment in the SM sample, at 12 mos post-diagnosis, the median survival in mos was 61.7 (CI 36.3 - 87) in the ADT group and 62 (CI 37.6 - 87.1) in the simulated ADT+D group (i.e., 0.3 mos simulated benefit of D).
  • A 0.8 mos simulated benefit was found if D was initiated 24 mos post diagnosis (in pts more likely to have HRPC).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963046.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


63. Richey SL, Culp SH, Wood CG, Corn PG, Jonasch E, Tannir NM: Outcome of patients (pts) with metastatic renal cell carcinoma (mRCC) treated with systemic therapy without cytoreductive nephrectomy (CN). J Clin Oncol; 2009 May 20;27(15_suppl):e16035

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The median overall survival (OS) time of pts treated with interferon alfa (IFN-α) without CN was 7.8 months (mos) [Flanigan et al.
  • We calculated OS time from date of diagnosis until date of death or last follow up.
  • We excluded pts who had embolization, radiofrequency ablation or cryotherapy of the primary tumor.
  • Median follow-up time is 9.7 mos (range: 1.2-49.2).
  • Median OS time for all pts is 10.7 mos (95% CI: 7.6-15.4).
  • 55 pts (62.5%) had clear-cell and 33 (37.5%) had non-clear cell histology, with median OS times of 15.1 mos (95% CI: 9.6-17.7) and 7.4 mos (95% CI: 4.4-13.0), respectively.
  • ECOG performance status (PS) at time of diagnosis was correlated with OS (HR 1.54; 95% CI: 1.16-2.05; p<0.01).
  • Pts with PS 0, 1, 2, and 3 had median OS times of 22.8 mos (95% CI: 5.7,*), 16.5 mos (95% CI: 8.1-24.7), 7.6 mos (95% CI: 5.7-11.9), and 7.1 mos (95% CI: 3.3-9.6), respectively.
  • Pts with clinical evidence of lymph node (LN) involvement had worse outcome,with median OS time of 7.6 mos (95% CI: 5.6-9.8) versus 17.2 mos (95% CI: 9.8-35.5) for pts without clinical evidence of LN involvement.
  • CONCLUSIONS: In this analysis, median OS time for pts with mRCC treated in the modern era with TT without CN is superior to historical experience with IFN- α.Compromised PS, LN involvement, and non-clear cell histology were associated with worse outcome.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962960.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


64. Sinibaldi VJ, Carducci MA, Moore-Cooper S, George B, Denmeade S, Drake CG, Walczak J, Pili R, Zahurak ML, Eisenberger MA: A randomized double blind phase I-II study to determine the tolerability/efficacy of two different doses of lenalidomide (L), CC- 5013, in biochemically relapsed (BR) prostate cancer (PC) patients (pts) (M&lt;sub&gt;0&lt;/sub&gt;) after local treatment (LT). J Clin Oncol; 2009 May 20;27(15_suppl):5130

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Pts were randomized to either 5 or 25 mg/day(d), PO, d 1-21 (28-d cycles); then stratified by PSADT (< 3, 3-8.9, ≥ 9 mos), LT and prior ADT.
  • Eligible pts had: rising PSA (≥1 ng/mL), M<sub>0</sub> disease, testosterone > 150 ng/mL, adequate bone marrow, renal, and hepatic function.
  • Baseline and Q 2 mos PSA's were processed after Q 6 mos of L, along with CT and bone scan.
  • Primary endpoints are safety and progression after 6 mo of L (defined by a confirmed ↑ in PSA > 25% over the baseline value or mets).
  • A sample size of 30 pts/arm provides an 85% power to detect a PSA progression rate of 40% (compared to 80% predicted ) with a Type I error = 0.05 (Fishers exact test).
  • 16 pts had PSADT <3 mos, 26 from 3-8.9 mos, and 17 ≥ 9 mos.
  • 22 /44 who completed 6 mos of L remained on L > 6 mos ( 7<sup>+</sup>-30<sup>+</sup> mos); including 7 pts ≥ 24 mos.
  • Of 44 pts, blinded evaluation of PSA's at 6 mos: 4 pts had ≥ 50% ↓, 22 had stable PSA,17 had PD, 1 too early .
  • Rash was DLT. Other Gr toxicities: appendicitis, abd pain, neck pain, venous thrombolic disease, fatigue, pruritus.
  • CONCLUSIONS: Preliminary data prior to unblinding the study treatment arms, from pooled data, suggest that L may be administered > 6 mos with acceptable toxicity, and is associated with PSA declines and long term stabilization in pts with BR.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964411.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


65. Salerrno May KS, Yang GY, Iyer RV, Chandrasekhar R, Wilding G, Khushalani NI, Yendamuri SS, Gibbs JF, Fakih M: Renal atrophy secondary to chemoradiation treatment of abdominal malignancies. J Clin Oncol; 2009 May 20;27(15_suppl):e15532

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Primary disease sites were pancreas (61.5%), periampullary (16.1%), stomach (10.8%), gastroesophageal junction (10%), and retroperitoneum (1.5%).
  • Median follow up was 9.4 months (range 0-55.4 mos).
  • Compensatory hypertrophy of the non-PK was not seen.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962316.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


66. Meyerhardt JA, Jackson McCleary N, Niedzwiecki D, Hollis D, Venook A, Mayer R, Goldberg R: Impact of age and comorbidities on treatment effect, tolerance, and toxicity in metastatic colorectal cancer (mCRC) patients treated on CALGB 80203. J Clin Oncol; 2009 May 20;27(15_suppl):4038

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Median follow-up was 23 mos.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961542.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


67. Ramanarayanan J, Pahuja S, Elefante AN, Hernandez-Ilizaliturri FJ: Abrogation of tumor necrosis alpha (TNF-alpha) pathway by anti-TNF therapy in hematological malignancies. J Clin Oncol; 2009 May 20;27(15_suppl):7093

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: We reviewed the English literature by conducting systematic MEDLINE using the terms TNF-, infliximab, adalimumab, etanercept, cancer therapy, hematologic malignancies, myelodysplastic syndrome (MDS), multiple myeloma (MM), myeloproliferative disease (MPD), chronic lymphocytic leukemia (CLL), and lymphoma from January 2001 to August 2008.
  • As a single agent, etanercept did not yield significant responses.
  • Improvement in constitutional symptoms were noted in at least 50% of patients with myelofibrosis(MF)/Ph- MPD.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961263.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


68. Bengala C, Bettelli S, Fontana A, Bertolini F, Sartori G, Malavasi N, Losi L, Del Giovane C, Luppi G, Conte P: EGFR gene copy number, KRAS and BRAF status, PTEN and AKT expression analysis in patients with metastatic colon cancer treated with anti-EGFR monoclonal antibodies ± chemotherapy. J Clin Oncol; 2009 May 20;27(15_suppl):e15055

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • So far EGFR GCN is available on 55 pts, KRAS and BRAF on 63 pts, PTEN in primary tumor (PT) on 36 pts and in metastatic (MTS) site on 24 pts, AKT on 19 pts.
  • It was 4.2 vs. 2.3 mos in pts with WT and mutated KRAS respectively (p: 0.001).
  • Median OS was 9.7 mos (2.03-49.0) and no statistically significant differences were observed according to the biomarkers status.
  • However a trend was observed for pts with KRAS WT 10.6 vs. 7.8 mos and for PTEN positive in PT: 9.0 vs. 5.67 mos.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964545.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


69. Gandara D, Kim ES, Herbst RS, Moon J, Redman MW, Dakhil SR, Hirsch F, Mack PC, Franklin W, Kelly K: S0536: Carboplatin, paclitaxel, cetuximab, and bevacizumab followed by cetuximab and bevacizumab maintenance in advanced non-small cell lung cancer (NSCLC): A SWOG phase II study. J Clin Oncol; 2009 May 20;27(15_suppl):8015

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] S0536: Carboplatin, paclitaxel, cetuximab, and bevacizumab followed by cetuximab and bevacizumab maintenance in advanced non-small cell lung cancer (NSCLC): A SWOG phase II study.
  • METHODS: Eligibility: treatment-naïve advanced stage non-squamous cell NSCLC, no requirement for EGFR positivity, PS 0-1, no brain metastases or hemoptysis.
  • Primary endpoint: feasibility defined by the frequency and severity of ≥grade 4 hemorrhagic toxicities.
  • Primary endpoint was met: grade ≥4 hemorrhage: 2% (95% CI: 0-7%).
  • Partial response (PR): 51/95 assessable (54%; 43%-64%); Stable disease (SD): 22/95 (23%).
  • Disease control rate (PR+SD): 77%.
  • With median follow up of 15 months (mos), PFS is 7 mos (18 pts remain progression-free) and OS is 14 mos.
  • EGFR IHC by H score (>0 vs 0) showed a nonsignificant trend toward improved survival: 15 vs 11 mos (p=0.14).
  • S0819, a Phase III trial of CB/P ± CX (plus B in eligible pts) is under development and is designed to validate EGFR FISH as a predictive biomarker.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962808.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


70. Natale RB, Natale RB: Concurrent chemotherapy immediately following erlotinib (E) or gefitinib (G) induced apoptosis in previously untreated patients with advanced or metastatic non-small cell lung cancer (NSCLC). J Clin Oncol; 2009 May 20;27(15_suppl):e19014

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Concurrent chemotherapy immediately following erlotinib (E) or gefitinib (G) induced apoptosis in previously untreated patients with advanced or metastatic non-small cell lung cancer (NSCLC).
  • However, a subset analysis of TRIBUTE pts with a never smoking history suggested that improved survival may occur when the pt population is partially enriched to increase the proportion with an EGFR-TKI induced apoptotic effect (Miller VA.
  • RESULTS: With a median follow-up of 24 mos, the median TTPs are 21+ mos and 7 mos and the median survivals are 31+ and 12 mos in groups A and B, respectively.
  • CONCLUSIONS: These data suggest that EGFR-TKI induced apoptosis may act synergistically with concurrent 1<sup>st</sup> line chemotherapy in pts with advanced or metastatic NSCLC and a new paradigm for incorporation of biologically targeted agents into chemotherapy regimens.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962621.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


71. Tannir N, Wong Y, Kollmannsberger C, Ernstoff MS, Perry DJ, Appleman LJ, Posadas E, Qian J, Ricker JL, Michaelson DM: Phase II trial of ABT-869 in advanced renal cell cancer (RCC) after sunitinib failure: Efficacy and safety results. J Clin Oncol; 2009 May 20;27(15_suppl):5036

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Eligibility criteria included progressive disease (PD) within 100 days of enrollment after at least 2 cycles of sunitinib, prior nephrectomy, and adequate organ function.
  • The primary endpoint was objective response rate (ORR) per RECIST by central imaging.
  • Median TTP was 4.9 mos [95% CI: 3.5-6.8] per central imaging.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962936.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


72. Fischbach NA, Spigel D, Brahmer J, Garst J, Robles R, Chung C, Wang L, Sing A, Lynch T, ARIES Investigators: Preliminary safety and effectiveness of bevacizumab (BV) based treatment in subpopulations of patients (pts) with non-small cell lung cancer (NSCLC) from the ARIES study: A bevacizumab (BV) treatment observational cohort study (OCS). J Clin Oncol; 2009 May 20;27(15_suppl):8040

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Preliminary safety and effectiveness of bevacizumab (BV) based treatment in subpopulations of patients (pts) with non-small cell lung cancer (NSCLC) from the ARIES study: A bevacizumab (BV) treatment observational cohort study (OCS).
  • Median F/U is 7.5 mos.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962849.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


73. Zhang W, Dahlberg SE, Yang D, Sandler AB, Brahmer JR, Schiller JH, Carbone DP, Johnson DH, Lenz H: Genetic variants in angiogenesis pathway associated with clinical outcome in NSCLC patients (pts) treated with bevacizumab in combination with carboplatin and paclitaxel: Subset pharmacogenetic analysis of ECOG 4599. J Clin Oncol; 2009 May 20;27(15_suppl):8032

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Multivariable Cox models adjusted for gender, PS, stage, adrenal, liver and bone mets were separately fitted for each SNP to obtain estimates of hazard ratios.
  • RESULTS: Median OS for the 133 patients was 10.3 mos (8.2-15.6) for PC and 13.0 mos (10.2-16.6) for BPC.
  • Median PFS was 4.6 mos (3.6-5.6) for PC & 6.5 mos (5.4-8.3) for BPC.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962832.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


74. Higano C, Alumkal J, Ryan CJ, Yu EY, Beer TM, Chandrawansa K, Katz T, Youssoufian H, Schwartz J, Prostate Cancer Clinical Trials Consortium: A phase II study evaluating the efficacy and safety of single agent IMC A12, a monoclonal antibody (MAb), against the insulin-like growth factor-1 receptor (IGF-IR), as monotherapy in patients with metastastic, asymptomatic castration-resistant prostate cancer (CRPC). J Clin Oncol; 2009 May 20;27(15_suppl):5142

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: Pts received IMC-A12 10 mg/kg IV every 2 wks; until evidence of progressive disease (PD), intolerable toxicity, or other withdrawal criteria were met.
  • PD by bone scan required at least 2 new lesions with confirmation at subsequent imaging per PCWG2.
  • 9 of 31 pts experienced disease stabilization for ≥6 mos (range: 7.4-12.5 mos), 5 pts (3 with PSA reduction) continue on IMC-A12.
  • Disease stabilization for > 6 months in 9 of 31 pts suggests that IMC- A12 may have modest antitumor activity.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964448.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


75. Rixe O, Dutcher J, Motzer R, Wilding G, Stadler WM, Garrett M, Pithavala Y, Kim S, Tarazi J, Rini BI: Diastolic blood pressure (dBP) and pharmacokinetics (PK) as predictors of axitinib efficacy in metastatic renal cell cancer (mRCC). J Clin Oncol; 2009 May 20;27(15_suppl):5045

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RESULTS: The median overall survival (mOS) for mRCC pts with at least 1 dBP measurement ≥90 mmHg (n = 59) during axitinib therapy was 130 weeks vs. 42 weeks (p < 0.01) for pts without any dBP ≥90 mmHg (n = 50).
  • The mOS of pts with an AUC below the median (605 ng.hr/ml; n = 54) was 69 weeks vs. 88 weeks (p > 0.05) for pts with an AUC above the median (n = 55).
  • Among pts with dBP ≥90 mmHg, mOS was 120 weeks and 131 weeks (p > 0.05) for pts with AUC below and above the median (n = 23 and 36), respectively.
  • Among pts without dBP ≥90 mmHg, mOS was 42 weeks and 43 weeks (p > 0.05) for pts with AUC below and above the median (n = 31 and 19), respectively.
  • An 82% increase in probability of a partial response was predicted for a 10 mmHg higher dBP during therapy.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962952.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


76. Kaseb AO, Iwasaki M, Javle M, Onicescu G, Garrett-Mayer E, Abbruzzese JL, Thomas MB: Biological activity of bevacizumab and erlotinib in patients with advanced hepatocellular carcinoma (HCC). J Clin Oncol; 2009 May 20;27(15_suppl):4522

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Current standard of care for advanced HCC is sorafenib based on median survival (MS) of 10.7 months (mos), median time to progression 5.5 mos.
  • RESULTS: The primary endpoint was the percent of pts alive and progression-free after 16 weeks of therapy (PFS<sub>16</sub>) based on historic median PFS of 3 to 5 mos.
  • Of the 57 pts enrolled, 14 (28%) had confirmed partial responses, 31 (62%) had stable disease and 5 (10%) had progressive disease.
  • The median PFS is 7.9 mos (95% CI 5.7, 9.5) and the OS is 12.8 mos, 95% CI (9.5, 17.9).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962725.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


77. Cabanillas ME, Waguespack SG, Bronstein Y, Williams M, Feng L, Sherman SI, Busaidy NL: Treatment (tx) with tyrosine kinase inhibitors (TKIs) for patients (pts) with differentiated thyroid cancer (DTC): The M. D. Anderson Cancer Center (MDACC) experience. J Clin Oncol; 2009 May 20;27(15_suppl):6060

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Until recently, tx for pts with progressive, RAI negative disease was limited.
  • METHODS: Adult pts with a diagnosis of DTC treated with single agent sorafenib (SOR) or sunitinib (SUN), and who had a baseline and at least 1 follow-up (f/u) scan after 3 months (mos) of therapy, were included.
  • 15 pts met inclusion criteria: 9 women, 6 men.
  • No pts were excluded due to progression or death before 3 mos.
  • Most patients had RAI negative disease.
  • Four pts had bone mets: 2 had XRT and had SD in bone, while the other 2 did not have XRT and had PD in bone.
  • At 12 mos PFS was 65% and OS was 85%.
  • Median f/u time was 16 mos.
  • Log (TG) significantly correlated with response to tx and therefore may have value as a surrogate marker of response.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961926.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


78. Finn RS, Press M, Dering J, Florance A, Platek G, Arbushites M, Koehler M, Johnston S: Progression-free survival (PFS) of patients with HER2-negative, estrogen-receptor (ER)-low metastatic breast cancer (MBC) with the addition of lapatinib to letrozole: Biomarker results of EGF30008. J Clin Oncol; 2009 May 20;27(15_suppl):1018

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We report a blinded analysis of HER-2, ER, and progesterone receptor (PR) expression for patients (pts) with HR+ MBC at first diagnosis or post-adjuvant relapse and response to Lap + Let versus Let.
  • The primary endpoint was PFS in HR+, HER-2+ MBC pts; secondary endpoints included PFS in the intent-to-treat population.
  • RESULTS: In 219/1286 (17%) HER-2+ (FISH+ or IHC3+) pts, a significant improvement in median PFS was observed for Lap + Let versus Let (8.2 v 3.0 mos, HR = 0.71, 95% CI 0.53, 0.96, p = 0.019).
  • No significant difference in median PFS was seen in 952 (74%) HER-2-negative pts (13.4 v 13.7 mos, HR = 0.90, 95% CI 0.77, 1.05, p = 0.188).
  • Pts with the lowest quartile of ER expression (H-score <160, n = 207) had a significant improvement in median PFS (13.6 mos v 6.6 mos, HR = 0.65, 95% CI 0.47, 0.9, p < 0.005).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27960731.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


79. Madan S, Kumar S, Lacy MQ, Dispenzieri A, Hayman SR, Buadi FK, Dingli D, Rajkumar SV, Gertz MA: Natural history of multiple myeloma (MM) relapsing after autologous stem cell transplantation (ASCT). J Clin Oncol; 2009 May 20;27(15_suppl):e19513

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • : e19513 Background: The outcome of patients with MM relapsing after ASCT used early in the disease course or after failure of initial therapy, is not well defined.
  • RESULTS: We studied 487 patients who had relapsed following a single ASCT, of whom 351 (72%) had an early SCT (≤ 12 mos from diagnosis).
  • The median estimated follow up for all patients was 27 mos, 50 mos and 69 mos from relapse, SCT and diagnosis respectively.
  • The median overall survival (OS) from the time of relapse was 30 mos for the early SCT group and 21 months for the late SCT group.
  • The median time to relapse following transplant was 15 mos (3-119) among early SCT group and 12 mos (3-76) among the late SCT group.
  • Among the early group, nearly a third of the patients achieved a PR or better to first salvage therapy (Table), with another third achieving stable disease and 25% of patients did not have response data.
  • The median progression free survival for the first salvage regimen was 8 mos; 18 mos for those with PR or better and 5 mos for those with SD as the best response.
  • Those with a durable response to transplant and those not requiring initiation of therapy for long periods after disease relapse have favorable disease biology and have prolonged survival after relapse.
  • The natural history of the disease provides a valuable benchmark for evaluation of newer treatment approaches.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27960950.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


80. Borczuk AC, Chen J, Parikh F, Powell CA, Taub RN: Use of laser capture microdissection to derive poor prognosis gene expression signatures of epithelial abdominal malignant mesothelioma. J Clin Oncol; 2009 May 20;27(15_suppl):e22098

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Use of laser capture microdissection to derive poor prognosis gene expression signatures of epithelial abdominal malignant mesothelioma.
  • : e22098 Background: Prior work in abdominal malignant mesothelioma (AMM) has established a poor prognosis profile of biphasic AMM when compared to more favorable prognosis epithelial AMM.
  • It is evident, however, that epithelial AMM shows heterogeneity in biologic behavior and prognosis.
  • Given improvements in therapy and survival in AMM, stratification of patients with epithelial AMM into favorable and poor prognosis subgroups is desirable and gene expression profiles may provide poor prognosis signatures to further guide therapy.
  • METHODS: Favorable and poor prognosis subgroups were defined as 1000 days of survival time (based on median survival of 90 patients with AMM at Columbia Presbyterian as of Sept 2007).
  • Fourteen frozen epithelial AMM (7 favorable prognosis, 7 poor prognosis) with high quality RNA were laser capture microdissected using a PALM Zeiss microscope and analyzed using Affymetrix U133 Plus 2 microarrays.
  • High expression of Nde1, UHRF1, and EZH2 by qPCR on a set of 32 AMM (using an upper quartile cutoff) was associated with poor survival (Log rank statistic p<.01, p<.003 and p<.03 respectively).
  • Immunohistochemistry performed on tissue microarrays of 122 AMM for p16 loss and increased EZH2, Col3A1 and UHRF1 immunoreactivity was associated with poor survival (Log rank statistic p<.0001, p<.009, p<.0001 and p<.012, respectively).
  • CONCLUSIONS: Using a training set of laser captured favorable and poor prognosis epithelial AMM, a 39-gene signature was obtained that is associated with prognosis.
  • Validation of several of the candidate genes by qPCR expression and immunohistochemistry was performed, confirming favorable and poor prognosis strata among the epithelial AMM.
  • Identification of poor prognosis epithelial AMM at the time of initial biopsy/tumor cytoreduction could lead to more aggressive primary therapeutic intervention.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963284.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


81. Kamoi K, Kawauchi A, Miki T, Aron M, Remer E, Haber G, Berger A, Crouzet S, Ricardo B, Gill I: Laparoscopic renal cryoablation: Risk factor analysis to predict oncologic outcomes with minimum 5-year follow-up. J Clin Oncol; 2009 May 20;27(15_suppl):5094

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In the 69 patients with biopsy-proven renal cell cancer (median follow-up 81 mos; range 60-132 mos), 5-year overall, disease-specific, and disease- free survival was 75%, 92%, and 82%, respectively, while 10-year overall, disease-specific, and disease-free survival was 46%, 83%, and 79%, respectively.
  • Relative risk of patients who has a history of radical nephrectomy for RCC treatment was 4.1 (95% CIs, 1.2 to 13.4), and 5.4 (95% CIs, 1.2 to 27.7) for disease-free survival and disease-specific survival, respectively.
  • Disease-specific survival of 92% at 5-years and 83% at 10-years is possible.
  • Preceding radical nephrectomy for RCC treatment was the only independent predicting factor for both disease-free and disease-specific survival.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964294.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


82. Scher K, Tisnado DM, Rose-Ash D, Rastegar A, Adams J, Ko CY, Ganz PA, Kahn KL: Physician and practice characteristics influencing tumor board attendance: Results from the provider survey of the Los Angeles Women's Health Study. J Clin Oncol; 2009 May 20;27(15_suppl):e17501

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: This cross-sectional study utilizes data obtained by surveying physicians of a population-based sample of women with incident breast cancer.
  • Physicians were queried regarding tumor board attendance, specialty (medical oncologist [MO], radiation oncologist [RO], surgeon indicating that the hospital at which most breast cancer surgeries are performed has an American College of Surgeons accredited program [ACOSSg] and surgeon without such affiliation [non-ACOSSg]), physician characteristics (gender, race, teaching involvement, patient volume, number of offices, ownership interest), and practice setting (practice type, size, reimbursement).
  • Weekly participation was reported by 63%, 92%, 47%, and 32% of MOs, ROs, ACOSSgs, and non-ACOSSgs (p < 0.01).
  • In comparison to the most prevalent specialty category (low volume ACOSSgs), high volume MOs attend more (p = 0.01), and low volume non-ACOSSgs attend less frequently (p = 0.00).
  • Tumor board agendas and formalized institution wide policies could be designed to further engage low frequency attendees as a means to promote multidisciplinary care and improve health outcomes.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963245.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


83. Arellano ML, Winton E, Pan L, Souza L, Sunay S, Lima L, McLemore M, Heffner LT, Langston A, Khoury HJ: Prognostic significance of leukopenia at the time of diagnosis in acute myeloid leukemia (AML). J Clin Oncol; 2009 May 20;27(15_suppl):7070

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic significance of leukopenia at the time of diagnosis in acute myeloid leukemia (AML).
  • : 7070 Background: In contrast to the poor prognosis associated with hyperleukocytosis, the prognostic significance of leukopenia at the time of diagnosis of AML is unknown.
  • Simultaneously obtained peripheral blood and marrow blasts were analyzed for cell surface expression of CD34, cKit, CXCR4, PCAM, VLA-2, VLA-3, VLA-4, VLA-5, and FLT3 using flow cytometry.
  • RESULTS: Patients' characteristics (gender, secondary vs. de novo, and cytogenetic [CTG] risk) were comparable between the 2 groups.
  • Leukopenic AML pts were older (median 56 vs. 53 years, p = 0.02), and had lower induction complete remission [CR] rates: 63% vs. 81% (p = 0.03) by univariate analysis.
  • Induction mortality was 0% for leukopenic and 5% for non-leukopenic pts.
  • In primary refractory pts, median survival was longer for leukopenic (11) vs. non-leukopenic (34) pts: 137 vs. 81 d (p = 0.026).
  • Median follow-up was 22 mos.
  • Event-free (EFS), disease-free (DFS), and overall survivals (OS) were lower in the leukopenic group: 12 vs. 14; 14 vs. 17; and 17 vs. 19 mos, respectively; but did not reach statistical significance.
  • The level of expression of cell surface adhesion molecules on blood and marrow blasts was comparable for the 2 groups.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961453.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


84. Vergote I, Finkler NJ, Hall JB, Melnyk O, Edwards RP, Jones M, Meng L, Brown GL, Rankin EM, Burke JJ 2nd, Rose PG: Randomized phase III study of canfosfamide (C, TLK286) plus pegylated liposomal doxorubicin (PLD) versus PLD as second-line therapy in platinum (P) refractory or resistant ovarian cancer (OC). J Clin Oncol; 2009 May 20;27(15_suppl):5552

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: 244 pts were planned with P refractory or resistant (progression within 6 mos. after P) OC following ≤ 2 P regimens, and measurable disease (RECIST).
  • Randomization was stratified by ECOG PS, best prior P response and bulky disease (≥ 5cm).
  • The 65/60 pts were well-balanced for disease characteristics and received a median 3/3.5 cycles per patient (range 1-11/0-17) of C + PLD/PLD, 35 pts (21/14) discontinued study treatment(s) due to the hold, respectively.
  • Non-hematologic AEs were similar for both arms, except the incidence of Grade 2-3 Palmar-Plantar Erythrodysesthesia (PPE) (9% vs. 21%) and stomatitis (17% vs. 23%) was lower and less severe with C+PLD vs. PLD.
  • Overall median PFS, the primary endpoint, was 5.6 mos. for C + PLD and 3.7 mos. for PLD (p = 0.7243, HR = 0.92).
  • In a planned analysis, 75 pts (40 /35) who were P refractory or primary P resistant observed a median PFS of 5.6 mos. for C + PLD vs. 2.9 mos. for PLD (p = 0.0425, HR = 0.55).
  • ORR for C + PLD was 15.0% (with 1 CR) vs. 5.7% for PLD.
  • Stable disease was observed 42.5% on C + PLD and 37.1% on PLD; median duration of SD was 7.4 mos. and 4.1 mos., respectively (p = 0.0439, HR = 0.49).
  • The median time to response was 2.8 mos. on C + PLD vs. 4.8 mos. on PLD.
  • In the P refractory or primary P resistant population, the median PFS was significantly longer for C+PLD than PLD alone.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962542.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


85. Sloan JA, Liu H, Sargent DJ, Satele D, Schaefer PL, Halyard MY, Grothey A, Garces YI, Brown PD, Loprinzi CL, Buckner JC: A patient-level pooled analysis of the prognostic significance of baseline fatigue for overall survival (OS) among 3,915 patients participating in 43 North Central Cancer Treatment Group (NCCTG) and Mayo Clinic Cancer Center (MC) oncology clinical trials. J Clin Oncol; 2009 May 20;27(15_suppl):9599

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • : 9599 Background: We have previously identified overall a single-item measure for baseline quality of life (QOL) as a strong prognostic factor for survival (Tan, ASCO 2008), and that fatigue was an important component of patient QOL (Sloan, 2007).
  • Cox proportional hazards models adjusted for the effects of overall QOL, performance score, race, disease site, age and gender.
  • RESULTS: Baseline fatigue was a strong predictor of OS for the entire patient cohort (CDF vs. nCDF: 31.5 mos vs >83.9 mos, p<0.0001).
  • The effect sizes were consistent across different disease sites (GI, esophageal, head and neck, prostate, lung, breast and others).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963750.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


86. Obasaju CK, Raju RN, Stinchcombe T, Couch LS, Jotte R, Kocs DM, Wang Y, Bromund J, Treat J, Socinski MA: Final results of a randomized phase II trial of pemetrexed (P) + carboplatin (Cb) ± enzastaurin (E) versus docetaxel (D) + Cb as first-line treatment of patients (pts) with stage IIIB/IV non-small cell lung cancer (NSCLC). J Clin Oncol; 2009 May 20;27(15_suppl):8037

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Final results of a randomized phase II trial of pemetrexed (P) + carboplatin (Cb) ± enzastaurin (E) versus docetaxel (D) + Cb as first-line treatment of patients (pts) with stage IIIB/IV non-small cell lung cancer (NSCLC).
  • In the TAX 326 trial, D + cisplatin was associated with a median survival of 11.3 mos vs. 10.1 mos for vinorelbine + cisplatin (P=.04).
  • Pts were equally randomized to 3 arms: (A) P 500 mg/m<sup>2</sup> and Cb AUC 6 every 3 wks × 6 cycles with E given orally as a loading dose of 1200 mg or 1125 mg followed by 500 mg daily until disease progression;.
  • CONCLUSIONS: First-line treatment with PCb was associated with a significantly longer overall survival than DCb in advanced or metastatic NSCLC.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962857.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


87. Carlson RW, O'Neill A, Vidaurre T, Gomez HL, Badve S, Sledge G, Eastern Cooperative Oncology Group: Randomized phase II trial of gefitinib plus anastrozole or fulvestrant in postmenopausal, metastatic breast cancer. J Clin Oncol; 2009 May 20;27(15_suppl):1013

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: This multi-institutional, single-stage, non-comparative, randomized phase II study tested the EGFR tyrosine kinase inhibitor gefitinib 250 mg daily PO plus endocrine therapy with either anastrozole 1 mg/day PO (AG Arm) versus fulvestrant 250 mg IM every 4-weeks (FG Arm).
  • Eligible pts were postmenopausal women with ER+ and/or PgR+ measurable metastatic breast cancer with no prior endocrine therapy for metastatic disease, no prior adjuvant AI or fulvestrant, no more than two chemotherapy regimens for metastatic disease, ECOG status 0-2, no CNS metastasis, and adequate bone marrow, liver, and renal function.
  • Primary endpoint was RECIST determined clinical benefit (CR+PR+SD for ≥6 mos) and secondary endpoints were toxicity and interaction of biomarkers with clinical benefit.
  • Treatment groups were balanced for race, age, ECOG status, and sites of disease.
  • Median follow-up is 35 mos.
  • Treatment was terminated for disease progression in 74% v 75%, toxicity 7% v 10%, death 1% v 3%, withdrawal 8% v 1%, and other 3% v 7% in the AG v FG arms, respectively.
  • Response rates are CR 3% v 4%, PR 21% v 17%, SD for ≥6 mos 18% v 17% for AG v FG.
  • Median PFS is 5.7 mos v 5.2 mos and median OS is 30.2 mos v 23.8 mos for AG v FG, respectively.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27960741.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


88. Wu Y, Kwok Y, Mirmiran A, Goloubeva O, Mannuel H, Dawson N, Amin P, Hussain A: Weekly paclitaxel (P) with concurrent external beam radiation (EBRT) and androgen deprivation therapy (ADT) in high-risk prostate cancer (PC) patients with or without prior prostatectomy (RP). J Clin Oncol; 2009 May 20;27(15_suppl):5122

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • : 5122 Background: EBRT with ADT (4 mos to 2-3 yrs) is standard treatment for high risk PC.
  • Treatment included ADT (4 or 24 mos, preplanned based on clinical presentation), P (40, 50, or 60 mg/m2/wk) x 7 with EBRT, and whole pelvis EBRT 45 Gy with 19.8 Gy boost (total 64.8 Gy) to prostate bed in RP pts and 25.2 Gy boost (total 70.2 Gy) to prostate in LAPC pts.
  • ADT for 4 mos was given in 29 pts and for 24 mos in 30 pts.
  • Median duration of f/u was 75.3 mos, OS 78%, biochemical progression 24/59 (41%) pts, clinical progression 11/59 (19%) pts.
  • Time to biochemical progression was similar between RP vs. LAPC (p = 0.17), between ADT 4 mos vs. 24 mos (p = 0.61), and between AA vs. W (p = 0.54).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964408.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


89. Hemavathy KC, Chang TH, Zhang H, Charles W, Goldberg A, Aithal S, Novetsky AD, Wang JC: Reduced expression of TGF beta1RII in agnogenic myeloid metaplasia is not due to mutation or methylation. Leuk Res; 2006 Jan;30(1):47-53

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Reduced expression of TGF beta1RII in agnogenic myeloid metaplasia is not due to mutation or methylation.
  • Agnogenic myeloid metaplasia (AMM) is characterized by bone marrow fibrosis and enhanced proliferation of megakaryocytes and CD34+ cells.
  • We have analyzed the factors that could lead to reduced expression of TGF beta1RII in CD34+ cells of AMM patients.
  • Our results demonstrate absence of mutations in the coding region and the promoter of this gene and absence of CpG methylation of its promoter in AMM patients.
  • Further studies on transcriptional regulation of TGF beta1RII involving its cis-regulatory elements, the interacting transcription factors and their association with HDAC will provide valuable information on the pathogenesis of AMM and are under current investigation.
  • [MeSH-major] DNA Methylation. Gene Expression Regulation / genetics. Mutation. Primary Myelofibrosis / metabolism. Receptors, Transforming Growth Factor beta / biosynthesis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16054691.001).
  • [ISSN] 0145-2126
  • [Journal-full-title] Leukemia research
  • [ISO-abbreviation] Leuk. Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Receptors, Transforming Growth Factor beta; 0 / Transcription Factors; EC 2.7.11.1 / Protein-Serine-Threonine Kinases; EC 2.7.11.30 / transforming growth factor-beta type II receptor; EC 3.5.1.98 / Histone Deacetylases
  •  go-up   go-down


90. Zhu Bd, Qie Yq, Wang Jl, Zhang Y, Wang Qz, Xu Y, Wang Hh: Chitosan microspheres enhance the immunogenicity of an Ag85B-based fusion protein containing multiple T-cell epitopes of Mycobacterium tuberculosis. Eur J Pharm Biopharm; 2007 Jun;66(3):318-26
Immune Epitope Database and Analysis Resource. gene/protein/disease-specific - Related Immune Epitope Information .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • To develop novel delivery system for tuberculosis (TB) subunit vaccine, biodegradable chitosan microspheres were prepared and used to deliver a fusion protein, Ag85B-MPT64(190-198)-Mtb8.4 (AMM for short), made from three Mycobacterium tuberculosis genes.
  • AMM-loaded microspheres were first characterized for their morphology, size, zeta potential, loading efficiency, and in vitro release of AMM.
  • C57BL/6 mice were immunized at weeks 1, 3 and 5 subcutaneously with AMM formulated in chitosan microspheres, in incomplete Freund's adjuvant (IFA), or in phosphate-buffered saline (PBS), respectively.
  • It was shown that the microspheres bound AMM quite efficiently (loading efficiency: >99%).
  • AMM-loaded chitosan microspheres were observed as aggregated shapes with the average particle size of 5.78+/-0.65 microm and zeta potential of 32.77+/-1.51 mV.
  • Following subcutaneous administration, splenocytes immunized with AMM in chitosan microspheres produced higher levels of IFN-gamma compared to administration of AMM in PBS upon stimulation with Ag85B and synthetic peptide MPT64(190-198).
  • The levels of Ag85B-specific IgG (H+L), IgG1 and IgG2a in sera of mice immunized with AMM in chitosan microspheres were also higher than those with AMM in PBS.
  • These results indicate that chitosan microspheres when used as a carrier for fusion protein AMM could elicit strong humoral and cell-mediated immune responses.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17280823.001).
  • [ISSN] 0939-6411
  • [Journal-full-title] European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft für Pharmazeutische Verfahrenstechnik e.V
  • [ISO-abbreviation] Eur J Pharm Biopharm
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Antibodies, Bacterial; 0 / Antigens, Bacterial; 0 / Bacterial Proteins; 0 / Cytokines; 0 / Epitopes, T-Lymphocyte; 0 / Recombinant Fusion Proteins; 0 / Tuberculosis Vaccines; 0 / Vaccines, Subunit; 0 / Vaccines, Synthetic; 82115-62-6 / Interferon-gamma; 9012-76-4 / Chitosan; EC 2.3.- / Acyltransferases; EC 2.3.1.- / antigen 85B, Mycobacterium tuberculosis
  •  go-up   go-down


91. Ishizone S, Koide N, Karasawa F, Akita N, Muranaka F, Uhara H, Miyagawa S: Surgical treatment for anorectal malignant melanoma: report of five cases and review of 79 Japanese cases. Int J Colorectal Dis; 2008 Dec;23(12):1257-62
MedlinePlus Health Information. consumer health - Melanoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Surgical treatment for anorectal malignant melanoma: report of five cases and review of 79 Japanese cases.
  • INTRODUCTION: Anorectal malignant melanoma (AMM) is a relatively rare disease.
  • Because of its poor prognosis, the optimal surgical treatment for AMM is still controversial and difficult to determine.
  • In this paper, we report five cases of AMM that have been treated by surgery and/or other methods at Shinshu University Hospital within the last decade.
  • We also review the present five cases along with 74 other Japanese cases reported between 1997 and 2006 and discuss the role of surgery in the treatment of AMM.
  • RESULTS AND DISCUSSION: Among our AMM patients, two who underwent radical abdominoperineal resection had long survival, while the other three patients who underwent palliative surgery had a poor outcome.
  • On the total of 79 AMM patients, those who underwent curative surgery had a better outcome than those who underwent palliative surgery (p < 0.0001).
  • Furthermore, the outcome of AMM patients at stages 0 and I was better than that of AMM patients at stages II, III, and IV (p < 0.0001).
  • There was no significant difference in survival between AMM patients with and without adjuvant chemotherapy.
  • CONCLUSION: In conclusion, AMM patients treated by curative surgery can expect long-term survival, although the usefulness of adjuvant chemotherapy for AMM patients is controversial.
  • [MeSH-major] Anus Neoplasms / surgery. Melanoma / surgery. Rectal Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Dis Colon Rectum. 1997 Jun;40(6):661-8 [9194459.001]
  • [Cites] Ann Surg. 2006 Dec;244(6):1012-7 [17122627.001]
  • [Cites] Am J Surg. 2005 Apr;189(4):446-9 [15820458.001]
  • [Cites] Ann Plast Surg. 1992 Jan;28(1):85-8 [1642415.001]
  • [Cites] Dis Colon Rectum. 1990 Oct;33(10):874-7 [1698595.001]
  • [Cites] Melanoma Res. 2004 Apr;14(2):147-50 [15057046.001]
  • [Cites] Gastroenterology. 1993 Jan;104(1):174-8 [8419240.001]
  • [Cites] Am Surg. 2006 Oct;72(10):917-20 [17058735.001]
  • [Cites] J Clin Pathol. 1963 Mar;16(2):126-32 [16811001.001]
  • [Cites] Dis Colon Rectum. 1995 Feb;38(2):146-51 [7851168.001]
  • [Cites] Dis Colon Rectum. 2002 Oct;45(10 ):1412-5; discussion 1415-7 [12394445.001]
  • [Cites] Br J Surg. 2004 Sep;91(9):1183-7 [15449271.001]
  • [Cites] Cancer. 1981 Apr 1;47(7):1891-900 [6164474.001]
  • [Cites] Surgery. 1990 Jan;107(1):1-9 [2296748.001]
  • (PMID = 18633625.001).
  • [ISSN] 0179-1958
  • [Journal-full-title] International journal of colorectal disease
  • [ISO-abbreviation] Int J Colorectal Dis
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


92. Ougari KE, Taneja C, Sofrygin O, Kaura S, Delea T: Cost-effectiveness of zoledronic (ZOL) acid plus endocrine therapy (ET) in premenopausal women with early breast cancer (EBC) from a Canadian perspective. J Clin Oncol; 2009 May 20;27(15_suppl):557

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • : 557 Background: The Austrian Breast and Colorectal Cancer Study Group Trial 12 (ABCSG-12) examined the efficacy of 3 years (yrs) of treatment with goserelin in combination with ET (anastrozole or tamoxifen) with or without ZOL 4 mg q6 mos in 1,803 premenopausal women with EBC (median age 45 yrs).
  • After a median follow-up of 47.8 mos (max 84 mos), risk of disease-free survival (DFS) events was reduced by 36% (HR = 0.64; p = 0.01) in patients (pts) who received ZOL (ZOL+ET) compared with those who did not (ET).
  • A Canadian healthcare system perspective and a lifetime timeframe were used.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27960672.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


93. Stamboulis E, Voumvourakis K, Andrikopoulou A, Koutsis G, Tentolouris N, Kodounis A, Tsivgoulis G: Association between asymptomatic median mononeuropathy and diabetic polyneuropathy severity in patients with diabetes mellitus. J Neurol Sci; 2009 Mar 15;278(1-2):41-3
MedlinePlus Health Information. consumer health - Diabetic Nerve Problems.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Asymptomatic median mononeuropathy (AMM) and diabetic polyneuropathy (DPN) often coexist and can be difficult to distinguish electrophysiologically.
  • Moreover, the potential association between AMM and DPN has not been extensively evaluated.
  • OBJECTIVE: We investigated the relation between AMM and DPN severity in consecutive diabetic patients.
  • METHODS: The non-dominant limb was studied electrophysiologically in 100 consecutive diabetic patients with no symptoms of carpal tunnel syndrome on the non-dominant side.
  • AMM was diagnosed based on previously validated electrophysiological criteria.
  • RESULTS: AMM was discovered in 28% of the study population (Adjusted Wald 95% CI: 20%-37%).
  • In multivariate logistic regression models increasing severity of DPN was independently associated with the presence AMM (Wald test=10.557, df=3, p=0.014).
  • Patients with DPN stage III and IV had a five-fold (OR=5.06, 95% CI=1.49-17.19) and a four-fold (OR=4.50, 95% CI=1.15-17.65) respectively increased likelihood to present with AMM in comparison to DPN stage I (reference group).
  • CONCLUSIONS: Our results confirmed the high incidence of AMM in diabetic patients.
  • AMM was present in a significant number of patients in the absence of DPN and the likelihood of AMM detection increased with increasing severity of DPN.

  • Genetic Alliance. consumer health - Diabetes.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19059612.001).
  • [ISSN] 0022-510X
  • [Journal-full-title] Journal of the neurological sciences
  • [ISO-abbreviation] J. Neurol. Sci.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  •  go-up   go-down


94. Grenacher PA, Schwarzwald CC: Assessment of left ventricular size and function in horses using anatomical M-mode echocardiography. J Vet Cardiol; 2010 Aug;12(2):111-21

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: To study the applicability of anatomical M-mode (AMM) for assessment of left ventricular (LV) size and function in horses, evaluate agreement with conventional M-mode (CMM), determine reliability, and establish reference intervals for AMM measurements.
  • METHODS: Two-dimensional and M-mode recordings were analyzed retrospectively.
  • Standard LV dimensions and indices of LV function, including time intervals, were measured in CMM and compared with AMM studies in long-axis (lx) and short-axis (sx) views.
  • RESULTS: The percentages of measureable cycles were 99%, 97%, and 90% for routine LV studies in CMM(sx), AMM(sx), and AMM(lx) mode.
  • For time intervals, >or= 93% of cycles could be measured using AMM compared to a maximum of 77% using CMM.
  • AMM(sx) measurements agreed well with CMM(sx) measurements for LV studies; the agreement of AMM(lx) with CMM(sx) was markedly lower.
  • CONCLUSIONS: AMM can replace CMM for assessment of LV dimensions in horses, but is not recommended for measurement of time intervals.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2010 Elsevier B.V. All rights reserved.
  • (PMID = 20615777.001).
  • [ISSN] 1875-0834
  • [Journal-full-title] Journal of veterinary cardiology : the official journal of the European Society of Veterinary Cardiology
  • [ISO-abbreviation] J Vet Cardiol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  •  go-up   go-down


95. Arnold R, Müller H, Schade-Brittinger C, Rinke A, Klose K, Barth P, Wied M, Mayer C, Aminossadati B, PROMID Study Group: Placebo-controlled, double-blind, prospective, randomized study of the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: A report from the PROMID study group. J Clin Oncol; 2009 May 20;27(15_suppl):4508

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: Treatment-naïve patients with histologically confirmed locally inoperable or metastasized well-differentiated NETs and a Karnofsky index >60 were randomized to receive either octreotide LAR 30 mg/month (mo) or placebo for 18 mos, or until tumor progression or death.
  • The primary endpoint was median time to tumor progression.
  • Secondary endpoints included objective tumor response rate (WHO criteria), measured every 3 mos, as well as symptom control and overall survival.
  • Median time to tumor progression in the octreotide LAR and placebo groups were 14.3 mos and 6 mos, respectively (HR: 0.34; 95% CI: 0.20-0.59; P=0.000072).
  • After 6 mos of treatment, stable disease was seen in 67% and 37.2% of patients treated with octreotide LAR and placebo, respectively.
  • Octreotide LAR demonstrates substantial tumor control and shows a more favorable antiproliferative response than placebo as two-thirds of patients treated with octreotide LAR achieved stable disease at 6 mos.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962687.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


96. Wang JC: Importance of plasma matrix metalloproteinases (MMP) and tissue inhibitors of metalloproteinase (TIMP) in development of fibrosis in agnogenic myeloid metaplasia. Leuk Lymphoma; 2005 Sep;46(9):1261-8
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Importance of plasma matrix metalloproteinases (MMP) and tissue inhibitors of metalloproteinase (TIMP) in development of fibrosis in agnogenic myeloid metaplasia.
  • Bone marrow fibrosis in AMM, with deposition, not only of interstitial and basement membrane collagen but also of fibronectin, vitronectin, laminin and proteoglycans, results from a disturbed balance between synthesis and proteolytic degradation of matrix protein.
  • Although TIMP and MMP play important roles in the development of fibrosing diseases of skin, liver and lung, only a few studies of TIMP and MMP in the formation of bone marrow fibrosis in AMM have been published.
  • The literature shows that TIMP-1 (both the total, complex and the free form) is significantly increased in AMM and other myeloproliferative syndromes (including polycythemia vera (PV) and essential thrombocytosis (ET)), while MMP-3 is significantly decreased, and levels of MMP-2 and MMP-9 are not different from control values.
  • Variance from control values for both TIMP-1 and MMP-3 is more evident in AMM than in PV and ET, thus further suggesting bone marrow fibrosis in AMM results from enhanced TIMP and decreased MMP activities.
  • [MeSH-major] Matrix Metalloproteinases / physiology. Primary Myelofibrosis / etiology. Primary Myelofibrosis / pathology. Tissue Inhibitor of Metalloproteinases / physiology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16109602.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Tissue Inhibitor of Metalloproteinases; EC 3.4.24.- / Matrix Metalloproteinases
  • [Number-of-references] 69
  •  go-up   go-down


97. Zhang S, Gao F, Wan D: Effect of misdiagnosis on the prognosis of anorectal malignant melanoma. J Cancer Res Clin Oncol; 2010 Sep;136(9):1401-5
MedlinePlus Health Information. consumer health - Melanoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effect of misdiagnosis on the prognosis of anorectal malignant melanoma.
  • OBJECTIVE: Anorectal malignant melanoma (AMM) is frequently subjected to misdiagnosis.
  • Here the effect of misdiagnosis on the prognosis of AMM was investigated.
  • METHODS: Between 1995 and 2007, 79 patients managed for AMM were reviewed; 46 (58.23%) of them had been misdiagnosed during the symptoms, while 33 (41.77%) cases had been diagnosed exactly not more than 1 week after the first visit.
  • RESULTS: The 1-, 2-, 3- and 5-year survival rates of AMM patients were 58, 33, 24 and 16%, respectively, and the median survival time was 14.0 months; 1-, 2-, 3- and 5-year survival rates of the misdiagnosed patients were 61, 22, 22 and 11%, respectively, and the median survival time was 14.0 months; 1-, 2-, 3- and 5-year survival rates of the patients not misdiagnosed were 55, 44, 25 and 25%, respectively, and the median survival time was 12.0 months.
  • Analyses based on Kaplan-Meier curves revealed no significant effect of misdiagnosis on the survival of AMM patients (P > 0.05).
  • Nevertheless, the diseases misdiagnosed significantly affect the prognosis (P = 0.009); AMM misdiagnosed as hemorrhoids had a poor prognosis, with a 1-year survival rate of only 29% and the median survival of only 6.0 months.
  • CONCLUSIONS: The misdiagnosed patients had relatively poor prognosis, but the effect of misdiagnosis on the prognosis was not significant; however, misdiagnosis of AMM as hemorrhoids seriously affected the prognosis.
  • [MeSH-major] Anus Neoplasms / diagnosis. Diagnostic Errors. Melanoma / diagnosis

  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Dis Colon Rectum. 1997 Jun;40(6):661-8 [9194459.001]
  • [Cites] J Clin Oncol. 2002 Dec 1;20(23):4555-8 [12454112.001]
  • [Cites] J Invest Dermatol. 2008 Aug;128(8):2031-40 [18305571.001]
  • [Cites] Am J Gastroenterol. 1975 Jan;63(1):79-83 [1119474.001]
  • [Cites] Cancer Invest. 2008 Jun;26(5):516-34 [18568775.001]
  • [Cites] Eur J Surg Oncol. 1996 Dec;22(6):598-601 [9005147.001]
  • [Cites] Lancet Oncol. 2006 Jul;7(7):575-83 [16814209.001]
  • [Cites] Cancer. 2004 Apr 1;100(7):1478-83 [15042682.001]
  • [Cites] Dis Colon Rectum. 1990 Oct;33(10):874-7 [1698595.001]
  • [Cites] Melanoma Res. 2004 Apr;14(2):147-50 [15057046.001]
  • [Cites] Melanoma Res. 2002 Aug;12(4):395-8 [12170190.001]
  • [Cites] Int J Colorectal Dis. 2004 Mar;19(2):121-3 [12942268.001]
  • [Cites] South Med J. 2001 Sep;94(9):880-5 [11592745.001]
  • [Cites] Clin Exp Dermatol. 2007 Sep;32(5):603-7 [17376215.001]
  • [Cites] Clin Colorectal Cancer. 2007 May;6(7):532-5 [17553203.001]
  • [Cites] Tumori. 2000 Jul-Aug;86(4):356-8 [11016729.001]
  • [Cites] J Surg Oncol. 1995 Feb;58(2):118-20 [7844981.001]
  • [Cites] Dis Colon Rectum. 1995 Feb;38(2):146-51 [7851168.001]
  • [Cites] Am J Gastroenterol. 1999 Nov;94(11):3202-10 [10566715.001]
  • [Cites] Dis Colon Rectum. 2002 Oct;45(10 ):1412-5; discussion 1415-7 [12394445.001]
  • [Cites] Br J Surg. 2004 Sep;91(9):1183-7 [15449271.001]
  • [Cites] Cancer. 1981 Apr 1;47(7):1891-900 [6164474.001]
  • [Cites] Surgery. 1990 Jan;107(1):1-9 [2296748.001]
  • (PMID = 20130908.001).
  • [ISSN] 1432-1335
  • [Journal-full-title] Journal of cancer research and clinical oncology
  • [ISO-abbreviation] J. Cancer Res. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


98. Boula A, Mantadakis E, Xilouri I, Foudoulakis A, Samonis G: Agnogenic myeloid metaplasia with pulmonary hematopoiesis. Hematology; 2005 Dec;10(6):501-3
Hazardous Substances Data Bank. HYDROXYUREA .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Agnogenic myeloid metaplasia with pulmonary hematopoiesis.
  • Agnogenic myeloid metaplasia (AMM) is characterized by bone marrow fibrosis, splenomegaly and leukoerythroblastic anemia and is frequently accompanied by extramedullary hematopoiesis (EMH).
  • Pulmonary interstitial EMH associated with myelofibrosis has rarely been described in the medical literature and is usually fatal.
  • We report the case of a 77-year-old man with agnogenic myeloid metaplasia (AMM) treated with hydroxyurea, who seven years after diagnosis presented with dyspnea and severe hypoxemia.
  • Radionuclide bone marrow scanning demonstrated increased tracer activity on the bases of both lungs, consistent with non-hepatosplenic EMH.
  • Pulmonary EMH is rare in patients with AMM, but should be considered in patients with hypoxemia and respiratory distress.
  • [MeSH-major] Hematopoiesis, Extramedullary. Primary Myelofibrosis / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16321815.001).
  • [ISSN] 1024-5332
  • [Journal-full-title] Hematology (Amsterdam, Netherlands)
  • [ISO-abbreviation] Hematology
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] X6Q56QN5QC / Hydroxyurea
  •  go-up   go-down


99. Luo Y, Wang B, Hu L, Yu H, Da Z, Jiang W, Song N, Qie Y, Wang H, Tang Z, Xian Q, Zhang Y, Zhu B: Fusion protein Ag85B-MPT64(190-198)-Mtb8.4 has higher immunogenicity than Ag85B with capacity to boost BCG-primed immunity against Mycobacterium tuberculosis in mice. Vaccine; 2009 Oct 19;27(44):6179-85
MedlinePlus Health Information. consumer health - Tuberculosis.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Tuberculosis (TB) remains a major infectious disease worldwide despite chemotherapy and BCG vaccine.
  • We have previously constructed a fusion protein Ag85B-MPT64(190-198)-Mtb8.4 (AMM).
  • In this study, we investigated the immunogenicity of the fusion protein AMM in a novel adjuvant of dimethyl-dioctyldecyl ammonium bromide and BCG polysaccharide nucleic acid (DDA-BCG PSN), and its capacity to boost BCG-primed immunity.
  • In addition, the ability of the subunit vaccine AMM to boost BCG-primed immunity against Mycobacterium tuberculosis was analyzed.
  • The fusion protein AMM induced more effective humoral and cell-mediated immune responses in mice than Ag85B alone.
  • Mice primed with BCG vaccination followed by boosting with AMM produced a stronger immune response and afforded a better protection against M. tuberculosis infection than mice immunized with BCG alone or BCG priming followed by boosting with Ag85B.
  • These findings suggest that AMM is a promising candidate subunit vaccine to enhance the protective efficiency of BCG.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19712772.001).
  • [ISSN] 1873-2518
  • [Journal-full-title] Vaccine
  • [ISO-abbreviation] Vaccine
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Adjuvants, Immunologic; 0 / Antibodies, Bacterial; 0 / Antigens, Bacterial; 0 / BCG Vaccine; 0 / Bacterial Proteins; 0 / Immunoglobulin G; 0 / Recombinant Fusion Proteins; 0 / Vaccines, Subunit; 82115-62-6 / Interferon-gamma; EC 2.3.- / Acyltransferases; EC 2.3.1.- / antigen 85B, Mycobacterium tuberculosis
  •  go-up   go-down


100. Wang JC, Chang TH, Goldberg A, Novetsky AD, Lichter S, Lipton J: Quantitative analysis of growth factor production in the mechanism of fibrosis in agnogenic myeloid metaplasia. Exp Hematol; 2006 Dec;34(12):1617-23

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Quantitative analysis of growth factor production in the mechanism of fibrosis in agnogenic myeloid metaplasia.
  • OBJECTIVE: The current study quantified the growth factors in megakaryocytes and monocytes and correlated them to the degree of fibrosis, as there is no quantitative analysis of growth factors from megakaryocytes or monocytes reported in patients with agnogenic myeloid metaplasia (AMM).
  • 1) We found that mRNA levels of transforming growth factor (TGF) beta1, platelet-derived growth factor (PDGF), and fibroblast growth factor (FGF) produced by the megakaryocytes were significantly elevated in AMM compared with those in normal controls (p < 0.05).
  • Although these growth factors were elevated severalfold in AMM compared with other myeloproliferative disorders (MPDs) including essential thrombocythemia and polycythemia vera, they were not statistically significant.
  • 3) The mRNA levels of these growth factors produced from CD14+ cells were not significantly elevated in AMM compared with other MPDs or controls; the AMM mRNA levels were significantly elevated only in some patients.
  • 4) The correlation of mRNA levels of these growth factors with the degree of myelofibrosis in AMM was significant with megakaryocytes (r = 0.73) but not with monocytes (r = 0.23).
  • 5) ELISA of the growth factors from the cultured megakaryocytes showed that in most of the patients with AMM and other MPDs, and in volunteer controls, the growth factors were undetectable, and only a few patients with AMM (three each of TGF-beta1 and PDGF and one of FGF) and other MPDs (two of TGF-beta1 and one each of PDGF and FGF) had significantly elevated protein levels of these growth factors.
  • CONCLUSIONS:. 1) In AMM, the mRNA levels of these fibrosing growth factors are significantly elevated in megakaryocytes, and they were only elevated in a few patients in the monocyte-macrophage lineages.
  • 3) A statistically significant correlation between the growth factor mRNA levels with the degree of myelofibrosis in AMM suggests that these fibrosing growth factors produced by the megakaryocytes may be associated with the etiology of bone marrow fibrosis in AMM.
  • 4) Failure to substantiate at the protein level that megakaryocytes are the main source of growth factors production suggests that other factors or cells initiating translation of the growth factors in the megakaryocytes may also be important in the process of bone marrow fibrosis in AMM.
  • [MeSH-major] Fibroblast Growth Factors / biosynthesis. Platelet-Derived Growth Factor / biosynthesis. Primary Myelofibrosis / metabolism. Transforming Growth Factor beta1 / biosynthesis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17157157.001).
  • [ISSN] 0301-472X
  • [Journal-full-title] Experimental hematology
  • [ISO-abbreviation] Exp. Hematol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Antigens, CD14; 0 / Platelet-Derived Growth Factor; 0 / RNA, Messenger; 0 / Transforming Growth Factor beta1; 62031-54-3 / Fibroblast Growth Factors
  •  go-up   go-down






Advertisement